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ABSTRACT OF THE DISSERTATION
Noninvasive Multi-Modality Studies of Cardiac Electrophysiology, Mechanics, and Anatomical
Substrate in Healthy Adults, Arrhythmogenic Cardiomyopathy, and Heart Failure
by
Christopher Andrews
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2018
Professor Yoram Rudy, Chair

Heart disease is a leading cause of death and disability and is a major contributor to healthcare
costs. Many forms of heart disease are caused by abnormalities in the electrical function of heart
muscle cells or the cardiac conduction system. Electrocardiographic Imaging (ECGI) is a
noninvasive modality for imaging cardiac electrophysiology. By combining recordings of the
voltage distribution on the torso surface with anatomical images of the heart-torso geometry,
ECGI reconstructs voltages on the epicardium. This thesis applies ECGI to novel studies of
human heart function and disease and explores new combinations of ECGI with additional
imaging modalities.
ECGI was applied in combination with late gadolinium enhancement (LGE) scar imaging MRI
in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC carries a high
risk of sudden cardiac death, and the hallmark feature of ARVC is the progressive replacement
of healthy myocardium with fibrous and fatty tissue. By combining ECGI and LGE in ARVC
patients we found that there are signs of conduction abnormalities before structural abnormalities
can be detected in ARVC patients. Electrical and structural abnormalities in ARVC patients coix

localized. We also found that PVCs, potential triggers for arrhythmia, originated in regions of
structural and electrical abnormalities.
ECGI was applied in combination with speckle tracking echocardiography (STE) to
longitudinally image heart failure patients undergoing cardiac resynchronization therapy (CRT).
STE is an echocardiographic technique for measuring strain (contraction) in the heart. CRT is a
highly effective treatment for heart failure, however, around 30% of patients do not respond to
the treatment. ECGI was more effective for predicting response to CRT than the current standard
ECG criteria or STE indices. The timing of peak contraction in STE did not accurately reflect the
electrical activation sequence. CRT caused improvements in contraction that persisted even
when pacing was disabled. CRT prolonged repolarization at the site of the LV pacing lead,
which may increase the risk of arrhythmia in CRT patients.
The above studies contribute novel observations of human disease physiology and demonstrate
the clinical feasibility and effectiveness of ECGI for noninvasive assessment of ARVC and CRT.

x

Chapter 1: Introduction
1.1 Heart Disease and Electrophysiology
Heart disease is a leading cause of death and disability and is a major contributor to healthcare
costs 1. The pumping function of the heart is controlled by synchronized contractions of heart
muscle cells called cardiomyocytes. Cardiomyocyte contractions are controlled by changes to the
voltage gradient across the cell membrane. The characteristic membrane voltage signal
associated with cardiomyocyte contraction is called the cardiac action potential. The first phase
of the action potential is an increase in membrane voltage known as depolarization.
Depolarization begins the process of cardiomyocyte contraction through a process known as
excitation-contraction coupling. The membrane voltage remains elevated and contraction
continues through the plateau phase of the action potentials. Finally, the membrane voltage
returns to resting levels and contraction ends due to a process known as repolarization. All
phases of the cardiac action potential are controlled by a delicate balance of ionic current flow
through specialized transmembrane proteins known as ion channels. In order for the heart to
pump blood efficiently, heart muscle cells must contract synchronously. Synchronization of
cardiomyocyte contractions is accomplished by a specialized conduction system within the heart
and electrical coupling between adjacent cells. When cardiomyocyte action potentials are
coordinated by this cardiac conduction system, the collective action potentials of all contracting
cells result in a voltage signal that can be measured from the body surface.

1

1.1.1 Electrocardiogram (ECG)
Recordings of the electrical activity associated with cardiac contraction were first made in the
1800s. The characteristic voltage signal on the body surface was named the “electrocardiogram”
(abbreviated ECG or EKG, interchangeably) by Willem Einthoven, who won the Nobel prize in
1924 for his research on the ECG 2. While the electronics for recording the ECG have improved
considerably (Einthoven’s ECG recording apparatus weighed over 600 pounds), ECG recordings
have evolved very little over the past 50 years. The current standard of practice is the 12-lead
ECG, which records the cardiac electrical activity from standardized locations on the chest and
limbs.

1.1.2 ECG Abnormalities and Arrhythmia
Many forms of heart disease are associated with ECG abnormalities. Alterations to any aspect of
the conduction system in the heart or the cardiac action potential can lead to abnormal ECG
findings. There are many mechanisms that cause these alterations, including structural damage
caused by heart attacks, genetic mutations that affect ion channels or other important structures,
and progressive heart diseases. Alterations to the normal ECG rhythm are known as arrhythmias
and range in severity from benign to imminently life-threatening. The most important diagnostic
tool for arrhythmias is the ECG.

1.2 Electrocardiographic Imaging
ECG recordings from the body-surface reflect the electrical activity of the entire heart, with
regions close to the recording electrodes having a larger contribution to the signal than more
distant regions. While the ECG is massively important to clinical cardiology, its resolution is
limited by the distance of the electrodes from the heart surface. Electrocardiographic Imaging
2

(ECGI) is a novel imaging technique that greatly improves upon the resolution of the standard
12-lead ECG. ECGI is performed by solving the inverse problem in electrocardiography.

1.2.1 Theoretical Background
The inverse problem is governed by Laplace’s equation (∇2 Φ = 0) and boundary equations on
the heart and torso surfaces 3. In plain terms, Laplace’s equation describes the relationship
between voltages on an inner surface (the heart) and an outer surface (the torso). Laplace’s
equation can be applied to the heart-torso geometry when there are no electrical sources between
the heart and torso surfaces. When Laplace’s equation holds, it is possible to apply boundary
conditions to calculate the value of the voltage on one of the surfaces when the position of the
inner surface relative to the outer surface is known. Solutions to Laplace’s equation for arbitrary
geometries can be formulated by discretizing the inner and outer surfaces and solving the
equation with the Boundary Element Method 4. Therefore, applying Laplace’s equation the heart
requires the position of the heart relative to the torso surface and knowledge of the boundary
conditions.
The first boundary condition applied to Laplace’s equation in ECGI states that the normal
derivative of voltage is zero at the torso surface. This condition holds because the air surrounding
the torso is an insulating medium that does not support current flow out of the body. The second
boundary condition is that the voltage on the heart surface is known. Applying these conditions
and solving for the voltage on the torso-surface is known as the forward problem in
electrocardiography. However, ECGI is concerned with the inverse problem in
electrocardiography. To solve for the inverse problem, the terms of the forward problem are
rearranged to formulate an equation for the voltage on the surface of the heart as a function of the
3

voltage on the torso surface, which can be easily measured non-invasively. While a unique
solution to the inverse problem exists, the inverse problem is “ill-posed.”
The term ill-posed means that small inaccuracies in the measurements of the input values may
produce very large errors in the output. Sources of inaccuracy in the electrocardiographic inverse
problem include noise in voltage measurements and small inaccuracies introduced by
representing the heart-torso geometry using discretized surfaces. Because these sources of noise
are unavoidable, regularization is employed to stabilize the solutions to the inverse problem. The
term regularization broadly encompasses various strategies that have been developed to stabilize
the solutions to ill-posed problems 5-10.

1.2.2 Methodology
ECGI is performed by combining ECG recordings from the torso of patients with non-invasive
imaging of the heart-torso geometry, then computing voltages on the heart by applying
regularization to the inverse problem. A schematic of the procedure is presented in Figure 1.1.
Approximately 250 ECGs are simultaneously recorded from the torso-surface. After the
recordings are obtained, patients are imaged using a computed tomography (CT) or magnetic
resonance imaging (MRI) scan to obtain images of the heart-torso geometry. A novel
contribution of this thesis was a modification of the imaging protocol to enable compatibility
with MRI. Compatibility is achieved by removing the electrode strips, which cannot be safely
worn in the magnetic field of an MRI scanner, and replacing them with MRI-visible marker
strips. This process is depicted in Figure 1.2. A major benefit of this modification is that it
avoids exposing patients to the ionizing radiation of a CT scan.

4

Figure 1.1 Schematic of the ECGI procedure. Body-surface potentials are recorded from the torso surface using a
portable recording system (top). The heart-torso geometry is obtained using a computed tomography (CT) or
magnetic resonance imaging (MRI) scan (bottom). The heart-torso geometry and torso potentials are combined and
the inverse problem is solved to reconstruct unipolar epicardial electrograms. Electrograms are processed to
determine local electrical parameters of interest (right frame).

1.2.3 Validation
The methodology of ECGI has been developed and extensively validated over multiple decades.
The technique was first validated using tank-torso studies. In these studies, animal hearts were
suspended in a human torso-shaped tank, and reconstructed voltages on the heart surface
(referred to as electrograms) were validated using directly-measured values 11. ECGI
reconstructions were also validated in humans by comparing reconstructed electrograms to direct
intraoperative mapping recordings 12. After many years of incremental improvements to the
technique and validation, the current implementation has been successfully applied to many
studies of human arrhythmia 13-15.

5

Figure 1.2 Modification to the Electrocardiographic Imaging (ECGI) procedure for MRI compatibility. Recording
electrodes (left) cannot be safely worn in the magnetic field of an MRI scanner. The electrodes are removed and
replaced with strips of MRI-visible markers (middle). The resulting images reveal the position of the electrodes
relative to the heart surface (right), which is necessary for the ECGI reconstruction.

1.3 Dissertation Organization
Chapters 2 and 3 of this thesis describe novel applications of ECGI. In each case, ECGI is
combined with additional noninvasive imaging techniques to study clinically important diseases.
A common thread of each of these studies, and a significant contribution of this thesis, is a
population of healthy adult controls. As ECGI is applied to additional forms of heart disease, a
control group of healthy adults is increasingly important. In each of the co-authored chapters that
follow, my role was to serve as the individual primarily responsible for data collection, analysis,
and manuscript preparation. The motivation and experimental techniques applied in Chapters 2
and 3 are described below. Chapter 4 concludes this thesis with remarks about the overall
contributions of these research efforts and future research directions that can build on the work
presented here.

6

1.4 Overview of Chapter 2
1.4.1 Study Design
Chapter 2 is an investigation of ECGI and structural imaging in 20 patients diagnosed with
arrhythmogenic right ventricular cardiomyopathy (ARVC). This study was performed in
collaboration with researchers at University College London. In this study, ARVC patients were
imaged with ECGI and late gadolinium enhancement (LGE) MRI. Patients in this study also
exercised using a supine bicycle. In many patients the exercise induced premature ventricular
contractions (PVCs), which are potential triggers of arrhythmia. We mapped the location of the
PVCs using ECGI and related the PVCs to structural and electrical abnormalities.

1.4.2 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
ARVC is a major cause of sudden death in young individuals and has a prevalence estimated as
high as 1 in 1000 16. The disease was originally called arrhythmogenic right ventricular dysplasia
(ARVD) because it was thought to be caused by a congenital defect in the right ventricle.
However, we now know the disease is caused by genetic defects in desmosomes, which are the
structures that connect cardiomyocytes 17. Desmosomal mutations progressively cause the
distinctive feature of ARVC, which is a loss of healthy heart muscle (myocardium) and
replacement by fibrous and fatty tissue 17. This progressive process of fibrofatty tissue
replacement is thought to cause abnormal conduction of the electrical signal for contraction,
which can lead to dangerous arrhythmias. The risk of sudden death in patients with ARVC may
be increased by sports activity. The rarity and progressive nature of ARVC make diagnosis and
risk stratification extremely difficult. In many cases, the first manifestation of ARVC is sudden
cardiac death. The only treatment proven to prevent sudden death is implantable cardioverter
7

defibrillator (ICD) implantation, however, implantation carries risks and primary prevention
indications remain a matter of debate 18,19. Because the key feature of ARVC is fibrofatty tissue
replacement, structural imaging techniques appear well-suited to for application to ARVC.
However, the regions of scar in ARVC may be small and diffuse, making them difficult to detect
with conventional imaging techniques. There is also evidence that the earliest signs of the
disease are electrical abnormalities.

1.4.3 Late Gadolinium Enhancement
Late gadolinium enhancement (LGE) is an imaging technique that can detect evidence of
structural scar in the heart 20. LGE imaging is performed by injecting patients with an MRIvisible contrast agent. Regions of tissue with increased extracellular space (e.g., regions of
cardiac scar) accumulate more of the contrast agent and appear brighter when imaged 21.

1.4.4 Key Findings
We found abnormal conduction and repolarization in ARVC patients compared to controls.
These abnormalities spatially co-localized with structural scar imaged with LGE. The majority of
patients had PVCs, which generally increased in frequency during exercise. The PVCs originated
in regions of electrical abnormalities and structural scar, making these regions a good target for
clinical intervention. ECGI detected conduction abnormalities in a young patient with ARVC
who had no other physical symptoms and no visible scar in LGE.

8

1.5 Overview of Chapter 3
1.5.1 Study Design
Chapter 3 is a prospective longitudinal study of heart failure in 30 patients undergoing cardiac
resynchronization therapy (CRT). Patients were imaged using ECGI and speckle-tracking
echocardiography (STE) prior to treatment, which allowed us to test how well the imaging
techniques were able to predict favorable response to treatment. We performed repeat imaging
after 3 and 6 months of treatment to observe how the heart physiology changes in response to
CRT. In addition to performing ECGI and STE in a control group of 20 healthy patients, we
performed tagged MRI on the controls.

1.5.2 Heart Failure and Cardiac Resynchronization Therapy (CRT)
In contrast to ARVC, which is relatively rare, heart failure is highly prevalent. An estimated 6.5
million American adults have heart failure, and this number is projected to grow to more than 8
million by 2030 1. While the 5-year fatality rate after hospitalization for heart failure is still very
high at 42.3%, it represents a substantial improvement thanks to continued advances in treatment
1.

One of the most significant advances in the treatment of heart failure is cardiac

resynchronization therapy (CRT). CRT is a pacemaker-based treatment that is designed to
improve the synchrony of contractions in the heart. Approximately 30% of heart failure patients
have regions of delayed electrical depolarization in their ventricles 22. The result of this delay is
that the contractions of the ventricles are not synchronized and do not pump blood as efficiently
as normal, synchronized contractions. This electrical delay manifests in the portion of the ECG
representing ventricular depolarization (known as the QRS complex) being wider than normal.
CRT is effective at correcting some of this dyssynchrony by pacing the heart at multiple
9

locations to resynchronize contractions. Large-scale clinical trials have shown that CRT
improves patient quality of life, reduces heart failure related hospitalizations, and prolongs
patient survival 23-26. While CRT has revolutionized treatment, it has been plagued by a
remarkably stable rate of about 30% of patients who do not respond to the treatment. Because the
dyssynchronous contraction in these patients is ultimately a mechanical phenomenon, there has
been debate over whether mechanical imaging techniques can measure the dyssynchronous
contractions and provide better patient selection criteria than the current ECG-based techniques.

1.5.3 Speckle-Tracking Echocardiography
Speckle-tracking echocardiography (STE) is an ultrasound-based imaging technique for
measuring strain. Strain is a mechanical property defined as a change in a material’s length
divided by its original length. Strain is useful in cardiology as a measure of the contraction of
heart muscle. Negative strain values indicate that the muscle contracted, while positive values
indicate that it stretched. STE measures strain in cardiac ultrasound images by tracking
characteristic speckled patterns that appear in these images and measuring the distances between
those patterns. STE is most commonly performed in 2D views of the heart. Key advantages of
STE include its high framerate and its safety in patients with implanted metal devices such as
pacemakers.

1.5.4 Tagged MRI
Tagged MRI is an MRI-based technique for imaging strain and is considered a gold standard for
measuring strain. Tagged MRI works by creating grid-shaped patterns in images of the heart,
then tracking the motion of the grids over time. Key advantages of tagged MRI over STE are that

10

it provides full 3D strain in the entire left ventricle and that the grid features are not affected by
their motion relative to the imaging plane.

1.5.5 Key Findings
The most effective predictor of response to CRT was the ventricular dyssynchrony measured
with ECGI. The time of peak contraction measured by STE did not accurately reflect the
electrical activation sequence, indicating that the strain curves are affected by other mechanical
factors such as opposing wall contractions and do not always reflect the sequence of electrical
activation. CRT caused beneficial improvements in contraction that persist even when pacing is
disabled. CRT also caused prolonged repolarization in the area of the left ventricular pacing lead,
which may increase the risk of arrhythmia in these patients.

11
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2.1 Abstract
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a significant cause
of sudden cardiac death in the young. Improved noninvasive assessment of ARVC and better
understanding of the disease substrate are important for improving patient outcomes.
Methods and Results: We studied 20 genotyped ARVC patients with a broad spectrum of
disease using Electrocardiographic Imaging (ECGI; a method for noninvasive cardiac
electrophysiology (EP) mapping) and advanced late gadolinium enhancement (LGE) cardiac
magnetic resonance scar imaging. Compared to 20 healthy controls, ARVC patients had longer
ventricular activation duration (median 52 vs 42 ms; p = 0.007) and prolonged mean epicardial
activation-recovery intervals (a surrogate for local action potential duration; median 275 vs 241
ms; p = 0.014). In these patients, we observed abnormal and varied epicardial activation
breakthrough locations, and regions of non-uniform conduction and fractionated electrograms.
Non-uniform conduction and fractionated electrograms were present in the early concealed phase
of ARVC. EP abnormalities co-localized with LGE scar, indicating a relationship with structural
disease. Premature ventricular contractions (PVCs) were common in ARVC patients with
variable initiation sites in both ventricles. PVC rate increased with exercise, and within
anatomical segments it correlated with prolonged repolarization, electrical markers of scar, and
LGE (all p < 0.001).
Conclusions: ECGI reveals EP substrate properties that differ in ARVC patients compared to
healthy controls. A novel mechanistic finding is the presence of repolarization abnormalities in
regions where ventricular ectopy originates. The results suggest a potential role for ECGI and
LGE in early diagnosis and non-invasive follow-up of ARVC patients.
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2.2 Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC) [abbreviations are defined in
Supplemental Table S2.1] is an important hereditary cause of sudden cardiac death in young
individuals with an estimated prevalence as high as 1:1000 1,2. The ARVC phenotype is
progressive, consisting of an early concealed phase, overt arrhythmias, and heart failure.
However, penetrance is variable and the first manifestation of the disease may be sudden cardiac
death 1,2. Diagnosis and treatment of ARVC are challenging, with implications for family
screening and risk stratification 3,4.
ARVC is characterized by fibro-fatty infiltration of the myocardium with an epicardial
predominance, suggesting that the disease progresses from epicardium to endocardium 5. Fibrofatty replacement in ARVC results from desmosomal mutations that lead to progressive
cardiomyocyte death 6. The desmosomal mutations cause decreased function of sodium channels
and gap junctions in cardiomyocytes 6,7. Exercise hastens disease progression by elevating
myocardial wall stress, especially in the right ventricle (RV) 8, and has been linked to episodes of
sudden cardiac death. Human and murine studies demonstrated that electrophysiological changes
precede the structural disease 9. Though originally described as a RV disease, there is increasing
evidence for non-classical presentation with both biventricular and left ventricular (LV)dominant disease 10.
Definitive diagnosis of ARVC requires histological demonstration of fibrofatty replacement of
myocardium or the presence of a known ARVC genotype. Biopsy is challenging because the
fibro-fatty infiltration may be patchy and epicardial. Genotypes linked to ARVC are present in
only 30-40% of cases. Current diagnosis utilizes a combination of structural, functional, and
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electrophysiological (EP) criteria 3. However, diagnosis is challenging because of the progressive
nature of ARVC and its early concealed phase. The only treatment proven to prevent sudden
cardiac death in ARVC patients is the implantable cardioverter defibrillator (ICD). However,
ICD implantation carries risks, and primary prevention indications remain a matter of debate 4,11.
Effective non-invasive modalities and improved understanding of ARVC arrhythmia
mechanisms are essential for accurate diagnosis and risk stratification. As stated in a recent
editorial, access to the epicardium for electrical measurements can enhance earlier disease
detection. However, direct epicardial access is challenging and limited to experienced clinical
centers 12. The present study employs a noninvasive method (Electrocardiographic Imaging:
ECGI; also referred to as Electrocardiographic Mapping (ECM) or body-surface mapping) 13 for
epicardial EP mapping and the latest generation of magnetic resonance imaging (MRI) for
cardiac structure (cardiac MRI (CMR) with advanced late gadolinium enhancement (LGE) using
motion correction reconstruction) 14. We applied ECGI and LGE to study the electrical and
structural substrates in ARVC patients. These two techniques are safe, noninvasive, and well
suited to longitudinal assessment of ARVC patients. The goal of this study is to provide insight
into the myocardial substrate and arrhythmia mechanisms in ARVC. It also constitutes a
preliminary exploration of the suitability of combined ECGI and LGE for diagnosis and risk
stratification of ARVC patients.

2.3 Methods
2.3.1 Patient Cohort
Twenty ARVC patients with a broad spectrum of structural and electrophysiological disease
were enrolled at the Heart Hospital, UCLH, London, UK. All patients were genotyped for
18

desmosomal mutations. Patient characteristics are summarized in Table 2.1 (additional clinical
characteristics provided in Supplemental Tables S2.2 and S2.3). The study was approved by
the National Research Ethics Service Committee London (14/LO/0360) and the Human Research
Protection Office at Washington University in St. Louis. All patients provided written informed
consent. The study conformed to the declaration of Helsinki.

Table 2.1
Patient ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Age
59
63
54
44
55
63
59
69
61
41
49
60
26
66
54
74
24
54
39
75

Gender
M
M
F
M
M
M
M
F
M
F
F
M
M
M
M
M
M
M
M
M

Mutation
JUP
PKP2
PKP2
DSP
DSP
PKP2
DSP
PKP2
DSP
DSP*
PKP2
DSG
PKP2
PKP2
PKP2
DSG
DSP
Negative
Negative
Negative

Major Criteria
1
1
2
1
1
3
1
0
1
1
3
3
0
2
2
1
1
2
2
2

Minor Criteria
1
3
3
3
5
3
3
2
2
1
2
2
3
1
0
3
0
2
2
3

ARVC patient characteristics including Task Force Major and Minor Criteria (numbers indicate how many Major and
Minor Criteria were observed). Mutation abbreviations: Plakoglobin (JUP), Plakophilin-2 (PKP2), Desmoplakin
(DSP), Desmoglein (DSG). Asterisk indicates variant of unknown significance.
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2.3.2 ECGI and MRI
The ECGI method was developed and validated in our laboratory and described previously 13. A
schematic of the procedure is presented in Supplemental Figure S2.1. Briefly, 256 uniformly
distributed body-surface electrocardiograms (ECGs) were recorded simultaneously using a
portable recording system (ActiveTwo, BioSemi, Netherlands). Patients exercised on a supine
ergometer for two minutes, followed by a ramp protocol of fifteen Watts/minute to a maximum
heart rate (HR) of 120 beats/minute. Recordings were performed in the supine position at rest,
during exercise, and immediately following exercise cessation. ECGI data were transferred to the
Rudy lab for data processing, map construction, and analysis.
Following the recording protocol, CMR was performed in a 1.5 T scanner (Magnetom Avanto,
Siemens Medical Solutions, Germany). Prior to the scan, recording electrodes were replaced
with MRI-visible markers so the electrode positions could be obtained in the same coordinate
system as the heart geometry. A navigated anatomical sequence was used so the ECGI electrical
and anatomical data could be merged. Conventional cine imaging and advanced LGE imaging
were conducted following the thorax scan. The contrast agent was 0.1mmol/Kg of Gadoterate
meglumine (Dotarem, Guerbet S.A., Paris, France) with LGE images acquired 5-15 minutes
post-contrast. The LGE sequence was a single shot steady state free precession phase sensitive
inversion recovery sequence 14 with motion corrected averaging and high resolution (typical
matrix: 144 x 256; voxel size 2.0 x 1.5 x 6.0 mm3). Two patients declined contrast injection.
Unipolar epicardial electrograms (EGMs) were reconstructed using previously described
methods 13 (additional ECGI methodology references in Supplement). Briefly, the heart-torso
geometry obtained from the MRI was used to compute a transfer matrix relating epicardial
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potentials to torso potentials. The inverse problem was solved to compute epicardial EGMs from
the recorded ECGs. Typically, 1000 EGMs were computed over the entire ventricular
epicardium. EGMs over the valve plane were excluded from analysis. Epicardial activation and
repolarization maps were constructed from the EGMs. ECGI reconstructions of sinus rhythm
were computed for each patient at resting HR prior to exercise and at elevated HR immediately
after exercise cessation. Additionally, the epicardial activation sequence was computed for each
unique premature ventricular contraction (PVC) morphology observed.

2.3.3 Analysis
Segmentation
ECGI maps and LGE images for each patient’s ventricles were divided into basal, mid, and
apical regions. Basal and mid regions were further subdivided into anterior, anterolateral,
inferolateral, and inferior regions. Apical regions were subdivided into anterior and inferior
regions. EGM measures for each region were computed as the mean value from all EGMs within
the region.
CMR Analysis
CMR analysis was performed using CVI42 software (Circle Cardiovascular Imaging
Inc.,Version 5.1.2[303], Calgary, Canada). For the analysis of LGE in the LV, epicardial and
endocardial borders were manually drawn on the short axis slices and the anterior RV insertion
point was identified. The Otsu semi-automated technique was used to quantify LGE and was
displayed on a bullseye plot as relative enhanced area (percentage) per segment on the 16segment American Heart Association model.
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For the analysis of the RV LGE, a segmentation model was created using short axis images.
Basal, mid and apical segments were identified using the papillary muscles as markers and
divided into anterior, anterolateral, inferolateral and inferior segments for the basal and mid RV
segments and as apical anterior and apical inferior segments for the RV apical segments.
The amount of RV LGE was quantified visually as 0 (no LGE), 1 (some LGE), or 2 (high LGE)
independently by 2 operators with 3 years of experience in CMR each (SR and HB). The
operators’ RV LGE quantification differed initially in 2 segments. Following additional analysis
of these segments, the reviewers reached a consensus. Analyses of the ECGI and CMR data were
conducted independently with investigators blinded to the results of the other modality.
Electrogram Analysis
Reconstructed unipolar epicardial EGMs were processed to compute local electrical measures.
Activation times (ATs) were computed as the time of steepest negative time-derivative of
voltage (-dV/dtmax) in the local QRS complex. Recovery times (RTs) were computed as the time
of steepest positive time-derivative (dV/dtmax) during the T-wave 15. Activation-recovery
intervals (ARIs, a surrogate for local action potential duration) were computed as the difference
between RT and AT. Supplemental Figure S2.2 defines these measures. ECGI-reconstructed
ARI values were validated against direct intraoperative epicardial mapping in humans (Zhang et
al. Online Supplement 16). Spatial gradient magnitudes of EGM measures were computed for
each EGM as the absolute value of the change between neighboring EGMs divided by the
distance between EGM locations, averaged across all neighbors. EGM amplitudes were
computed as the peak-to-peak voltage during the QRS complex. Fractionation was quantified
using the number of steep downward deflections between QRS onset and the start of the T-wave.
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Additional details of the fractionation quantification and sample EGMs are provided in
Supplemental Figure S2.3. The earliest 10% of ATs were considered the epicardial initiation
site of a PVC. PVC occurrence rates per EGM at a given epicardial site were computed as the
number of times the EGM met the above criterion divided by the total number of beats recorded
during the study.
Statistical Analysis
Fractionation values within anatomical segments are presented as z-scores compared to a group
of 20 healthy adults. Electrical measures in the ARVC study population were compared to
healthy controls using Wilcoxon rank-sum tests. Exercise changes were assessed using Wilcoxon
signed-rank tests. Cohort data are presented as medians and quartiles. Substrate and PVC rate
comparisons were performed using Spearman correlation coefficients computed using Matlab
software (The MathWorks, Inc., Natick, Massachusetts, USA).

2.4 Results
2.4.1 Electrical Substrate at Rest
Abnormal sinus rhythm activation and conduction were common in the ARVC patients. The
normal epicardial activation pattern is well described
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and a representative control is presented

in Figure 2.1. Generally, the earliest epicardial activation appears as a breakthrough, most
commonly in the anterior RV, and the basal lateral LV is usually the latest region to activate (Fig
2.1A). The normal sinus activation of healthy adult hearts does not have regions of discontinuous
conduction or fractionated EGMs (Fig 2.1A and 2.1B, left). In contrast to the normal activation
sequence, we observed abnormal and varied epicardial breakthrough locations, regions of
discontinuous conduction, and fractionated electrograms in the ARVC study population.
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Figure 2.1 Electrical substrate in a healthy adult. (A) Sinus rhythm activation with a typical RV epicardial
breakthrough (asterisk) and normal conduction. RV (1) and LV (2) unipolar EGMs have a normal morphology free
of fractionation. (B) Schematic maps of normal electrical properties in anatomical regions based on 20 control
subjects. Left: fractionation z-score. Right: Fridericia-corrected ARI. The maps show absence of fractionation and
ARI values within the normal range. AT: activation time. RA: right atrium. LA: left atrium. RV: right ventricle. LV:
left ventricle. ARI: activation-recovery interval. EGM: electrogram.

Figures 2.2-4 present activation and conduction patterns seen in ARVC patients. In two patients
with advanced disease (63 and 66 years old, respectively) we observed earliest epicardial
breakthrough in the LV (Fig 2.2A and 2.3A). One of these patients had normal epicardial EGMs
(Fig 2.2A), while we observed low-amplitude fractionated EGMs in the other (Fig 2.3A). ECGI
resolved activation and conduction abnormalities in a 26-year-old patient who did not have any
Major Task Force Diagnostic Criteria. In this patient, we observed fractionated EGMs and non24

uniform conduction near the earliest epicardial breakthrough site (Fig 2.4A). ARVC patients had
fractionation scores within anatomical regions that ranged from values within the control range
(Fig 2.2B, top) to values which were several standard deviations above the control distribution
(Fig 2.3B and 2.4B, top). While some patients had high fractionation scores, we did not observe
EGMs in these patients with deflections after the QRS complex (late potentials) that are
commonly associated with re-entrant arrhythmias (Fig 2.2A-4A). The abnormal conduction in
ARVC patients compared to controls was reflected in statistically longer total duration of
epicardial activation (p = 0.007, Control: 42 [36-47] ms, ARVC: 52 [44-64] ms) and steeper
mean epicardial gradients of AT (p = 0.018, Control: 0.24 [0.21-0.28] ms/mm, ARVC: 0.31
[0.26-0.37] ms/mm).
Repolarization in ARVC patients was prolonged compared to controls, and this prolongation was
often spatially heterogeneous. Figure 2.1B (right) presents a schematic map of mean ARI values
in epicardial segments for a representative control. Control values were homogenous and fell
within the range of values previously reported 17. In contrast, Figures 2.2B and 2.3B (middle)
show prolonged ARI values in ARVC patients. As demonstrated in Figure 2.2B (top), regions of
normal ARI values may co-exist with regions of long ARIs. Mean ventricular ARIs during
resting sinus rhythm (Fridericia rate correction applied) were significantly longer than control
values (p = 0.014, Control: 241 [230-262] ms, ARVC: 275 [238-300] ms). While ARIs were
prolonged in ARVC patients, we did not observe increased spatial gradients of repolarization or
total duration of epicardial repolarization (Supplemental Table S2.4).
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Figure 2.2 Electrical substrate of a patient (Patient 6) with advanced disease and a high PVC rate (18.69%). (A)
Ventricular epicardial breakthrough during sinus rhythm was abnormal, with earliest activation originating from the
basal inferior LV (asterisk). RV (1) and LV (2) unipolar EGMs had normal QRS morphology. (B) EGM
fractionation was not abnormal compared to controls (top). Fridericia-corrected ARIs were prolonged compared to
control values (middle). Concentrated LGE was visible in the inferior RV (bottom). (C) MRI image of extensive
LGE, which was confined to the subepicardial RV (indicated by yellow arrows). PVC: premature ventricular
contraction.

The presence of T-wave inversion on clinical ECG (clinical ECG findings in Supplemental
Table S2.2) was strongly associated with ARI prolongation. ARVC patients with T-wave
inversion (Fridericia rate correction applied) had significantly longer mean ARI values than
those without inversion (p = 0.010, With Inversion: 300 [269-313] ms, Without Inversion: 238
[231-262] ms). However, ECGI identified a patient without T-wave inversion whose mean
epicardial ARI was longer than any control, as well as a patient with T-wave inversion whose
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mean epicardial ARI was within the lowest quartile of the control values (Supplemental Table
S2.5).
As expected, mean epicardial ARI (uncorrected for HR) shortened due to exercise (p < 0.001).
Total RT (p = 0.002), mean epicardial RT gradients (p = 0.007), and mean EGM amplitude (p <
0.001) also decreased due to exercise. Total AT, mean epicardial AT gradients, and fractionation
were unaffected by exercise (Supplemental Table S2.6).
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Figure 2.3 Electrical substrate of a patient (Patient 14) with biventricular disease and a moderate PVC rate (1.11%).
(A) Sinus rhythm breakthrough was abnormal, with earliest epicardial activation originating from the basal lateral
LV (asterisk). RV (1) and LV (2) unipolar EGMs were fractionated (note the voltage scale of low-amplitude EGM
1). (B) Regions of high fractionation were present in both ventricles (top), and Fridericia-corrected ARI values were
prolonged compared to control values (middle). LGE was visible in both ventricles (bottom). (C) MRI image of
LGE showing scar in both ventricles (yellow arrows).2.4.2 Electrical Substrate during Stress
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Figure 2.4 Electrical substrate of a 26-year-old male (Patient 13) with early disease and no observed PVCs. (A)
Sinus rhythm epicardial breakthrough occurred in the inferolateral RV (asterisk in inset) with early activation of the
RV free wall. There was a region of non-uniform conduction and fractionated unipolar EGMs (1) between these
sites. Remote LV unipolar EGM (2) had a normal morphology. (B) Fractionation in the RV was much greater than
control values (top) while Fridericia-corrected ARI values were within the normal range of controls (middle).
Minimal LGE was visible in the LV (bottom). (C) MRI showed minimal abnormalities (arrow).

2.4.3 Structural (CMR) Substrate
Advanced LGE revealed a spectrum of scar burden in the ARVC patients. There was scar in 72%
of ARVC patients agreeable to contrast. Three patients had isolated RV LGE, seven had isolated
LV LGE, three had biventricular LGE, and five had no scar. Six patients in the study cohort had
no Task Force CMR defects. Of these six, three had visible LV LGE. Panels B (bottom) and C
of Figures 2.2-4 illustrate the broad spectrum of LGE observed in the study population.
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2.4.4 Relationship of Electrical and Structural Substrates
LGE scar spatially co-localized with EP substrate abnormalities, and the relationship between
CMR scar and EP abnormalities was stronger in the LV than in the RV. The amount of LV LGE
within anatomical segments correlated with EGM markers of abnormal depolarization including
low amplitude EGMs, increased number of deflections per EGM, and increased AT spatial
gradients. LV LGE correlated with prolonged resting ARI values and increase in ARI shortening
during and post exercise (Supplemental Table S2.7). RV LGE values within anatomical
segments did not correlate with EGM markers of abnormal depolarization, but did correlate with
prolonged ARIs at rest and post-exercise. RV LGE correlated with ARI shortening due to
exercise (Supplemental Table S2.8).
The results from Patient 6 (Fig 2.2) and Patient 14 (Fig 2.3) illustrate the above findings. Patient
6 has an RV anatomical scar that does not extend to the epicardium, as determined from LGE
(Fig 2.2C). The absence of scar on the epicardium is reflected in the local EGMs (EGM 1, Fig
2.2A), which appear normal. This is also reflected in the normal fractionation z-scores (Fig 2.2B,
top). Patient 14 has a similar RV anatomical scar, which lacks clear epicardial involvement (Fig
2.3C). However, in this case, the ECGI reconstructed epicardial EGMs at this location (EGM 1,
Fig 2.3A) are low amplitude and fractionated, indicating EP abnormality at the epicardium. The
same patient also has an LV scar which is visible on the epicardial aspect of the lateral LV. For
this scar, the corresponding epicardial EGMs (EGM 2, Fig 2.3A) are fractionated, indicating
coexistence of abnormal anatomical and EP substrates on the epicardium.
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2.4.5 Ventricular Ectopy
Ventricular ectopy was common in the ARVC patients and occurred more frequently as heart
rate increased following exercise. We observed PVCs in fifteen of twenty ARVC patients, with a
total of 41 distinct morphologies. The sites of earliest epicardial activation of the PVCs were
spread across both ventricles, with greater involvement of RV and basal locations. A schematic
diagram of the earliest epicardial activation sites for all PVC morphologies is provided in Figure
2.5.
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Figure 2.5 Schematic diagram of earliest epicardial activation of all observed PVC morphologies. Each marker
represents a unique PVC morphology, with the number indicating the number of times the morphology was
observed during the study. Marker color and shape identify patient ID (indicated below diagram). Sites near the
epicardial aspect of the septum are shown on the edge of the RV.
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Figure 2.6 PVC onset and initiation sites of a patient (Patient 6) with a high PVC burden (18.69%). (A) Timecourse of observed PVCs in relation to exercise and schematic map of PVC initiation sites. The different PVC
initiation sites are labeled A, B, and C and color coded. PVCs occurred only after the onset of exercise, and
morphology C appeared only once near peak HR (B) Activation isochrone maps of the three distinct PVC
morphologies observed in this patient. Asterisks indicate PVC initiation sites. Morphology B showed very a broad
region of early epicardial activation, indicating a possible sub-epicardial origin and possible conduction system
involvement. HR: heart rate.

The PVC rate within anatomical segments correlated with prolonged ARIs, ARI shortening due
to exercise, low voltage EGMs, increased deflections per EGM, and LGE scar (all correlations p
< 0.001). The PVC rate within anatomical segments did not correlate with increased gradients in
AT, RT, or ARI. Figures 2.6 and 2.7 show the temporal occurrence and spatial location and
propagation of PVCs in two patients. The substrates for these patients are presented in Figures
2.2 and 2.3, respectively. Supplemental Table S2.9 summarizes the correlations between PVC
rate and structural and EP substrate measures.
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Figure 2.7 PVC onset and initiation sites of a patient (Patient 14) with a moderate PVC burden (1.11%). (A) Timecourse of observed PVCs in relation to exercise and schematic map of PVC initiation sites. Note that morphology C
is partially obscured in the post-exercise recording period. (B) Activation isochrone maps of the three distinct PVC
morphologies observed in this patient. Asterisks indicate PVC initiation sites.

2.5 Discussion
This is the first evaluation of ECGI in ARVC patients. ECGI was sensitive enough to detect EP
substrate differences between ARVC patients and healthy controls. By combining ECGI with
LGE, we determined correlations between EP abnormalities and LGE scar. These correlations
indicate that the EP abnormalities detected with ECGI are markers of disease progression.
Importantly, new findings regarding properties of the EP and scar substrates included prolonged
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epicardial ARIs and a relationship of PVC rate within a region to repolarization, EP markers of
scar, and LGE.

2.5.1 ARVC Scar Substrate
Ventricular LGE was variable in location and extent. LV LGE was a more frequent finding than
RV LGE. LV LGE co-localized with traditional markers of EP scar assessed using ECGI, as
reflected by its correlation with lower voltage EGMs and increased fractionation. This finding
mirrors prior ECGI studies that found regions of scar assessed with LGE or single-photon
emission computed tomography to have lower voltage EGMs and increased fractionation 18. In
the RV, we did not observe a strong relationship between LGE and traditional EP markers of
scar. This is consistent with prior work comparing invasive EP mapping to RV LGE, which
found that nearly 50% of electrical scar substrates in the RV were not confirmed by LGE 19.
Prior studies have suggested that the absence of RV LGE findings could be attributed to the thin
RV wall, which complicates LGE in the RV 20. Alternatively, it is possible that EP abnormalities
in the RV manifest in the presence of minimal scar or scar that is diffuse and not easily resolved
with current imaging techniques.

2.5.2 Prolongation of Repolarization
There are multiple mechanisms which could contribute to the ARI prolongation observed in this
study. Functional changes in ionic currents due to ARVC mutations could contribute to
prolonged repolarization. Studies linking INa current to Plakophilin-2 mutations provided the first
evidence that ARVC may have some features of a channelopathy 21. While the focus of research
efforts in this area has largely been on depolarization, it is possible that repolarizing currents are
altered as well. K v1.5 channels localize to the intercalated disc and associate with Na v1.5 22,23,
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and K v1.5 function depends on N-cadherin, an intercalated disc protein 24. A mutation in KCNE2
that inhibits trafficking of Kv1.5 to the intercalated disc causes prolonged repolarization 25. While
we are unaware of direct evidence suggesting that this mechanism is involved in ARVC, it is an
interesting avenue for exploration.
Another mechanism which may contribute to prolonged repolarization is progression of the heart
failure phenotype associated with ARVC. Heart failure is a known end-stage complication of
ARVC 4, but systolic impairment of varying degrees can appear in either or both ventricles in the
absence of clinical heart failure 10. Action potential prolongation is a hallmark of heart failure
along with functional downregulation of potassium currents, slow conduction, and abnormal
calcium homeostasis 26. It is possible that these features develop in ARVC patients either
globally or locally as the disease progresses and surviving myocardium is subjected to increasing
strains because of fibrofatty tissue replacement.
Finally, myocardial uncoupling can increase the effects of any action potential duration
prolongation mechanisms. Myocardial uncoupling facilitates gradients in repolarization by
decreasing the electrotonic coupling between cells 27. Fibrofatty replacement acts to uncouple
cells by decreasing the local density of excitable cells. Reduction in the number and size of gap
junctions in the intercalated disc causes further uncoupling in ARVC, and has been reported even
in histologically normal regions of myocardium 6.
In our data, ARI prolongation correlated with LGE in both ventricles. This suggests that the
uncoupling effect of the scar, altered mechanical strains in regions of scar, or both may be
important to the development of prolonged repolarization. The uncoupling effect of ventricular
scar could also contribute to the correlation we observed between stress-related ARI shortening
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and LGE in both ventricles, as both rate increase and sympathetic stimulation have a greater
effect on cardiomyocytes that are less electrically coupled. While our population size is not
sufficient to draw conclusions about the age progression of the ARVC phenotype, we note that
the group included two patients in their twenties, both of whom had ARI values within the
normal range. This suggests that action potential prolongation in ARVC patients may develop as
the overall phenotype progresses. Mean epicardial ARIs were generally longer in patients with
precordial lead T-wave inversion. However, there were patients with and without T-wave
inversion who were exceptions to this relationship, indicating that ECGI offers improved
sensitivity and specificity for detecting prolonged repolarization. Additionally, ECGI provides
spatial information about ARI prolongation, which was spatially heterogeneous in ARVC.

2.5.3 Arrhythmia Triggers (PVCs)
The ability of ECGI to panoramically map the whole heart in a single beat allowed us to localize
PVCs, determine the frequency of each unique PVC morphology, and correlate ectopic
frequency with the EP and scar substrates. The overall rate of PVCs was increased by exercise.
We found that PVC rate within anatomical segments correlated with local ARI prolongation,
increased ARI shortening due to exercise, low voltage EGMs, fractionated EGMs, and LGE.
The hallmark finding of progressive scar formation in ARVC is compatible with the possibility
of re-entrant circuit formation. Prior work demonstrated conduction slowing at elevated heart
rates in ARVC patients 28. In the present study, we found evidence of slow conduction in the
form of longer total activation times and steeper activation gradients relative to controls.
However, we did not observe the dynamic conduction slowing at elevated HRs that Finlay et al.
reported 28. This discrepancy could be attributable to the difference in HRs investigated. In the
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present study, patients exercised to a peak HR of 120 beats/min, whereas the patients in the
Finlay et al. study were paced at an interval just below the ventricular refractory period.
The combination of scar, slow conduction, and prolonged repolarization could facilitate
unidirectional block and reentrant arrhythmia. Important signatures of re-entrant arrhythmia are
EGM fractionation and late potentials. We did not observe late potentials in the reconstructed
EGMs. This stands in contrast to ECGI studies of post-infarction scar-related ventricular
tachycardia, which found a high prevalence of late potentials with re-entry circuits closely
related to the EP substrate 29. While this could indicate that re-entrant arrhythmias are less
prevalent in ARVC, it is important to note the significant differences in the anatomy of the scars
in each population. Post–infarction scars are often large and heterogeneous, with large islands of
surviving myocardium, especially in the border zone. The ARVC scar substrate, on the other
hand, accumulates gradually over time and is typically diffuse, originating from the epicardium.
It is possible that the lower regional density of surviving myocardium in ARVC scar makes it
difficult to resolve late potentials in EP mapping of ARVC patients.
Focal mechanisms may cause arrhythmia triggers in ARVC patients. Focal triggered activity is
commonly observed in isolated myocytes in the form of early afterdepolarizations or delayed
afterdepolarizations. Early afterdepolarizatons at plateau potentials are caused by recovery and
re-activation of ICa, with the delayed rectifier currents, IKr and IKs, playing an important role 30.
We observed that PVC rate correlated with regions of prolonged ARI, a surrogate for local action
potential duration, including during stress when ICa is augmented by beta-adrenergic stimulation.
Action potential duration prolongation increases the window for ICa re-activation and early
afterdepolarization formation. In the intact heart, electrotonic coupling between myocytes acts as
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a current sink for depolarizing currents. Reduced coupling, caused by scar and gap junction
abnormalities in ARVC, can increase the likelihood of focal activity by decreasing the current
sink effect. The observed correlation between PVC rate and electrical and LGE markers of scar
suggests that an uncoupling effect is present at PVC initiation sites. It is interesting to note that
Myles et al. 31 found that focal activity was more common in the RV, which they attributed to
reduced coupling in the thin RV wall compared to the LV. In our study, we found greater overall
ectopy in the RV.

2.5.4 Clinical Implications
The progressive nature of ARVC and its early concealed phase complicate diagnosis and
treatment. CMR currently plays a valuable role in the evaluation of ventricular structure and
function. The current Task Force criteria do not include LGE, but acknowledge that it may be
included in future revisions 3. Our data show that combined ECGI and LGE could increase the
sensitivity for detecting substrate abnormalities in ARVC patients, including young patients with
little or no Task Force MRI and ECG criteria. LGE and ECGI are compatible with the current
use of CMR in the diagnosis and longitudinal assessment of ARVC. These imaging techniques
can be performed in addition to the conventional CMR assessment to provide a thorough
characterization of structural, functional, and EP abnormalities. In the present study, we report a
spectrum of abnormalities using these techniques and demonstrate a relationship between the
imaged substrates and ventricular ectopy. Since ventricular ectopy may play a causal role in
triggering arrhythmias, combined ECGI and LGE may have a role in risk stratification.
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2.5.5 Limitations
This study is a first evaluation of combined ECGI and LGE in ARVC patients and, therefore,
evaluated a relatively small group of twenty patients. Because CMR is commonly
contraindicated in patients with implanted devices, we only recruited patients without ICDs.
While this choice enabled us to image LGE in the study cohort, a drawback is that none of the
patients in this study had prior episodes of ventricular tachycardia. Therefore, this study cohort is
not well-suited for evaluating sudden cardiac death risk stratification. Further studies are
necessary to explore this application of these techniques. The current study evaluated patients
ranging in age from 24 to 75 years old; however, only three patients were younger than 41 years
old. Future studies should evaluate whether this approach can detect the presence of ARVC in
young, asymptomatic and genotype-positive individuals. Larger studies of a wide range of ages
and genotypes are important for exploring the progression of the disease, including how the EP
and scar substrates change over time. Prior studies demonstrated that strain imaging may be
effective for detecting the early stages of ARVC and for risk stratification 32,33. Future studies
could combine ECGI and strain imaging into a multi-modality approach for ARVC diagnosis
and risk stratification. Exercise and LGE data were collected from the ARVC patients, but not
controls. These data are needed to establish ranges for healthy controls. Additional data are
necessary to determine the specificity of ECGI and LGE criteria for diagnosis of ARVC.

2.5.6 Conclusion
ECGI in combination with advanced LGE reveals a spectrum of electrical and structural
substrate abnormalities in ARVC patients. This combination may improve sensitivity for
detecting ARVC substrate abnormalities. These data suggest a role for combined ECGI and LGE
in early diagnosis, non-invasive follow-up, and risk stratification of ARVC patients.
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Chapter 2 Appendix
Supplemental Figure S2.1: The ECGI Procedure

CT or MRI Scan

Images

Schematic diagram of the ECGI procedure. A computed tomography (CT) or magnetic resonance imaging (MRI)
scan provides the geometry of the epicardial surface and the locations of the recording electrodes on the body
surface in the same coordinate system (top). The body surface potential distribution is obtained from 256
simultaneously recorded electrocardiograms (bottom). Solving the inverse problem (middle gray box) yields
epicardial potentials and electrograms, from which activation times, recovery times, and other parameters of interest
are derived (right frame).
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Supplemental Figure S2.2: Activation Time, Recovery Time, and Activation-Recovery
Intervals

Diagram of unipolar electrogram (EGM) Activation Time (AT), Recovery Time (RT), and Activation-Recovery
Interval (ARI). Temporal derivatives (bottom) were computed from EGMs (top). ATs were computed as the time of
steepest negative time-derivative of voltage (-dV/dtmax) in the local QRS complex. Recovery Times were computed
as the time of steepest positive time-derivative (dV/dtmax) during the T-wave. To eliminate noise effects from RT
values, T-waves were lowpass-filtered using a 30 Hz Butterworth filter before determining RT. ARIs (a surrogate
for local action potential duration) were computed as the difference between RT and AT.
EGM: electrogram
AT: Activation Time
RT: Recovery Time
ARI: Activation-Recovery Interval
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Supplemental Figure S2.3: Electrogram Fractionation

Diagram of electrogram (EGM) deflections for a normal EGM (left) and a low-amplitude fractionated EGM (right,
shown on the same scale). The normal EGM had a single deflection (left, circle) while the fractionated EGM had 3
deflections (right, circles). Insets (large box) show fractionated EGM QRS voltage and dV/dt on enlarged scale.
Fractionation was quantified by counting the number of steep downward deflections between the QRS onset and the
start of the T-wave. Temporal derivatives (dV/dt, bottom) were computed from unipolar EGMs (top). Downward
deflections were regions of EGMs with a negative dV/dt. Multiple deflections occurred when there was a positive
dV/dt between downward deflections. The thresholds for steep downward deflections were:
1) Deflection peak-to-peak voltage amplitude ≥ 10% of the EGM peak-to-peak voltage amplitude
2) Deflection –dV/dt ≥ 70% of the EGM maximum –dV/dt
Additionally, both values were required to be ≥ 5% of the corresponding median values for all EGMs to prevent the
detection of noise in flat EGMs as fractionation.
EGM: electrogram
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Supplemental Table S2.1: Manuscript Abbreviations

Abbreviation
ARVC
RV
LV
EP
ICD
ECGI
MRI
CMR
LGE
ECG
HR
EGM
PVC
AT
RT
ARI

Meaning
Arrhythmogenic Right Ventricular Cardiomyopathy
Right Ventricle
Left Ventricle
Electrophysiological
Implantable Cardioverter Defibrillator
Electrocardiographic Imaging
Magnetic Resonance Imaging
Cardiac Magnetic Resonance
Late Gadolinium Enhancement
Electrocardiogram
Heart Rate
Electrogram
Premature Ventricular Contraction
Activation Time
Recovery Time
Activation-Recovery Interval
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

59
63
54
44
55
63
59
69
61
41
49
60
26
66
54
74
24
54
39
75

M
M
F
M
M
M
M
F
M
F
F
M
M
M
M
M
M
M
M
M

Mutation

JUP - c.2039G>A, W680X
c.148_151delACAG, p.S50fsX110
c.1799delA, p.V600fsX655
c.817_818insA, p.Q273fsX288
c.G4477T:p.E1493X
c.2197_2202delinsG, p.A733fsX740
c.3045delG, p.S1015fsX1017
c.2146-1G>C
c.G4477T:p.E1493X
c.C5178A:p.N1726K*
c.2489+1G>A
c.G3C:p.M1I
c.2489+1G>A
c.2197_2202delinsG, p.A733fsX740
c.2146-1G>C
c.G3C:p.M1I
c.C3337T:p.R1113X
Desmosomal gene negative
Desmosomal gene negative
Desmosomal gene negative

LV Morphological Abnormalities

Scar

ECG Abnormalities

Arrhythmias

Task Force
Criteria

+
+
+
+
+
+
+
+
+
+
-

+
-

+
+
+
+
+
+
+
+
+
+
+

+
+
+

+
+
-

+
-

+
+
+
+

+
+
+
+
+
+
+
+

+
+
-

+
-

+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+

+

+

V1-3
V1-4
V1-5
V5-6
V1-4
V1-4
V5-6
V1-3
V1-4
V1-6
V1-4
V1-5

+
-

+
+
+
+
+
+
+
-

+
+
+
+
-

JUP: Plakoglobin
PKP2: Plakophilin-2
DSP: Desmoplakin
DSG: Desmoglein
RWMA: Regional Wall Motion Abnormality
LV: Left Ventricular
RV: Right Ventricular
LGE: Late Gadolinium Enhancement
SAECG: Signal Averaged Electrocardiogram
NSVT: Non-Sustained Ventricular Tachycardia
SVT: Sustained Ventricular Tachycardia
VE: Ventricular Extrasystole
VT: Ventricular Tachycardia

+

+
+
+
+
+
+
+
-

+
+
+
+
+
+
+
+
+
+
+
+
+

-

Major
Major
Major
Major
Major
Minor
Minor
Minor
Major
Minor
Major
Major
Minor
Major
Major
Minor
Major
None
None
None

1
1
2
1
1
3
1
0
1
1
3
3
0
2
2
1
1
2
2
2

1
3
3
3
5
3
3
2
2
1
2
2
3
1
0
3
0
2
2
3

NSVT/SVT
T wave Epsilon Positive Terminal S NSVT/SVT indeterminate >500 VE's VT Study Family
RV LV
Systolic
Wall
Systolic
Wall
Dilation Thinning RWMA Dysfunction Anurysm Dilation Thinning RWMA Dysfunction Anurysm LGE LGE Biopsy Inversion Waves SAECG wave >55ms superior axis or inferior axis per 24 hrs Inducible History Major Minor

RV Morphological Abnormalities

Clinical characteristics of ARVC study population. Asterisk indicates gene variant of unknown significance.

JUP
PKP2
PKP2
DSP
DSP
PKP2
DSP
PKP2
DSP
DSP
PKP2
DSG
PKP2
PKP2
PKP2
DSG
DSP
-

ID Age Gender Gene

Genetics

Supplemental Table S2.2: Patient Clinical Characteristics

Demographics
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Supplemental Table S2.3: Holter PVC Findings

ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Age
59
63
54
44
55
63
59
69
61
41
49
60
26
66
54
74
24
54
39
75

Gender
M
M
F
M
M
M
M
F
M
F
F
M
M
M
M
M
M
M
M
M

PVC Count
59
620
1028
10
1000
2364
1111
784
>3000
56
642
681
52
26
38
1056
56
3496
890
>3000

Monomorphic/Poloymorphic Morphology
Monomorphic
LBBB
Polymorphic
LBBB+RBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Polymorphic
LBBB+RBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Polymorphic
LBBB+RBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB
Monomorphic
LBBB

Summary of 24-hour Holter findings from patient clinical records.
LBBB: Left bundle branch block morphology
RBBB: Right bundle branch block morphology

48

Supplemental Table S2.4: ARVC–Control Group Comparisons

Parameter
Total Activation Time (msec)
Total Recovery Time (msec)
Mean Epicardial ARI (msec, Fridericia Rate-Correction)
Mean Epicardial EGM Amplitude (mV)
Mean Deflections Per-Electrogram
Mean Epicardial Activation Time Gradient (ms/mm)
Mean Epicardial Recovery Time Gradient (ms/mm)
Mean Epicardial ARI Gradient (msec, Fridericia Rate-Correction)

Control
Median Q1
42
36
134
126
241
230
2.28
2.00
1.06
1.03
0.24
0.21
1.06
0.95
1.17
1.07

Q3
47
152
262
3.03
1.06
0.28
1.22
1.38

ARVC
Median Q1
52
44
129
120
275
237
2.58
1.69
1.09
1.03
0.31
0.26
0.93
0.85
1.21
1.05

Q3
64
146
300
2.96
1.18
0.37
1.05
1.48

P
0.007
0.273
0.014
0.735
0.086
0.018
0.060
1.000

Significance
**
*

*

Median, quartiles, and Wilcoxon rank sum comparison of ECGI EP parameters in healthy adults (Controls) and
ARVC patients. Highlighted rows (yellow) indicate statistically significant differences between Control and ARVC
groups.
Significance levels:
*** p < 0.001
** p < 0.01
* p < 0.05
Q1: First Quartile
Q3: Third Quartile
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Supplemental Table S2.5: Mean Fridericia-Corrected Epicardial ARI (msec) in Controls
and ARVC Patients with and without T-Wave Inversion
Controls
Median
241

Q1
230

Q3
262

ARVC: T-Wave Inversion
Min
206

Max
274

Median
300

Q1
269

Q3
313

Min
218

ARVC: No T-Wave Inversion
Max
330

Median
238

Q1
231

Q3
262

Min
226

Max
285

Median, quartiles, Range, and Wilcoxon rank sum comparison of resting ARI (Fridericia rate-correction applied) in
Controls and ARVC patients with and without T-Wave Inversion. Group difference ARVC with T-Wave Inversion
is significantly different than controls at p < 0.001 level and ARVC without T-Wave Inversion at p < 0.01 level.
Q1: First Quartile
Q3: Third Quartile
Min: Minimum value observed in group
Max: Maximum value observed in group
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Supplemental Table S2.6: Exercise Changes in ARVC Parameters

Parameter
Total Activation Time (msec)
Total Recovery Time (msec)

Resting HR
Median Q1 Q3
53
46
66
130
120 150

Elevated HR
Median Q1 Q3
57
47
66
106
91 120

P
0.658
0.002

Significance
**

Mean Epicardial ARI (msec, uncorrected for HR)

275

235

313

186

173

203

< 0.001

***

Mean Epicardial EGM Amplitude (mV)
Mean Deflections Per-Electrogram
Mean Epicardial Activation Time Gradient (ms/mm)

2.57
1.09
0.33

1.60 2.94
1.03 1.18
0.26 0.38

2.08

1.28 2.50
1.05 1.22
0.27 0.35

< 0.001

***

Mean Epicardial Recovery Time Gradient (ms/mm)
Mean Epicardial ARI Gradient (msec, Fridericia Rate-Correction)

0.94

0.87 1.06
1.07 1.49

0.70

0.60 0.88
1.01 1.38

0.007
0.687

1.22

1.09
0.30
1.12

0.872
0.260
**

Median, quartiles, and Wilcoxon signed-rank comparison of ECGI EP parameters in ARVC patients at Resting HR
and Elevated HR after exercise. Highlighted rows (yellow) indicate statistically significant differences between
Control and ARVC groups.
Significance levels:
*** p < 0.001
** p < 0.01
* p < 0.05
Q1: First Quartile
Q3: Third Quartile
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Supplemental Table S2.7: Correlation of EP Substrate to LV Late Gadolinium
Enhancement

Parameter

CC

P

Significance

EGM Amplitude

-0.42

< 0.001

***

Deflections Per-EGM
AT Spatial Gradient

0.52
0.24

< 0.001

***

0.001

**

Resting ARI

0.29

< 0.001

***

Exercise ARI
RT Spatial Gradient

0.10
-0.09

0.190
0.232

ARI Spatial Gradient

0.05

0.485

Exercise ARI Shortening

0.31

< 0.001

***

Spearman correlation coefficients of LV LGE and EP substrate parameters. Highlighted rows (yellow) indicate
statistically significant correlations between LV LGE and EP substrate parameters.
Significance levels:
*** p < 0.001
** p < 0.01
* p < 0.05
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Supplemental Table S2.8: Correlation of EP Substrate to RV Late Gadolinium
Enhancement

Parameter

CC

P

Significance

EGM Amplitude

-0.02

0.755

Deflections Per-EGM
AT Spatial Gradient

-0.05
-0.15

0.472
0.051

Resting ARI

0.30

< 0.001

***

Exercise ARI
RT Spatial Gradient

0.17
-0.05

0.027
0.502

*

ARI Spatial Gradient

-0.10

0.197

Exercise ARI Shortening

0.36

< 0.001

***

Spearman correlation coefficients of RV LGE and EP substrate parameters. Highlighted rows (yellow) indicate
statistically significant correlations between RV LGE and EP substrate parameters.
Significance levels:
*** p < 0.001
** p < 0.01
* p < 0.05
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Supplemental Table S2.9: Correlation of LGE and EP Substrate with Regional Rate of
Ventricular Ectopy

Parameter

CC

P

Significance

EGM Amplitude

-0.21

< 0.001

***

Deflections Per-EGM
AT Spatial Gradient

0.20
0.04

< 0.001

***

Resting ARI
Exercise ARI

0.35
0.28

< 0.001
< 0.001

RT Spatial Gradient

-0.06

0.232

ARI Spatial Gradient
Exercise ARI Shortening

0.00
0.30

0.943
< 0.001

***

LV LGE
RV LGE

0.50
0.35

< 0.001
< 0.001

***
***

0.457
***
***

Spearman correlation coefficients of PVC rate within anatomical regions and EP substrate parameters and LGE.
Highlighted rows (yellow) indicate statistically significant correlations between PVC Rate and substrate parameters.
Significance levels:
*** p < 0.001
** p < 0.01
* p < 0.05
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Chapter 3: Excitation and Contraction of the
Failing Heart in situ and Effects of Cardiac
Resynchronization Therapy

Christopher Andrews (BS), Gautam K. Singh (MD), Brian P. Cupps (PhD), Michael K. Pasque
(MD) and Yoram Rudy (PhD)
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3.1 Abstract
Background: Cardiac resynchronization therapy (CRT) is an effective treatment for heart failure
(HF) with benefits that include reverse remodeling of the HF phenotype. Despite the success of
CRT, the rate of nonresponders remains around 30%. Many small studies showed promising
results applying speckle tracking echocardiography (STE) strain imaging to patient selection, but
larger studies showed no benefits over standard criteria. Improvements to CRT require a more
complete understanding of the physiological changes of reverse remodeling and the relationship
between electrical and mechanical measures of synchrony.
Methods: We imaged 20 healthy controls and imaged 30 CRT patients longitudinally using
electrocardiographic imaging (ECGI, a method for noninvasive cardiac electrophysiology
mapping) and STE. We computed dyssynchrony with each technique and compared their relative
effectiveness for predicting response to CRT. We quantified CRT-induced remodeling of
electrical and mechanical physiological parameters. We measured the electromechanical delay
between activation and peak strain within LV segments. We additionally performed tagged MR
imaging on the healthy controls to provide a high-resolution 3D maps of activation, contraction,
and repolarization in healthy human hearts.
Results: The delay between mean lateral LV and RV electrical activation time, determined with
ECGI, was the best predictor of beneficial reduction in LV end systolic volume and
outperformed mechanical indices (Spearman’s Rho: -0.722, p < 0.001). The mean
electromechanical delay within anatomical segments was similar in controls and HF patients,
however, the HF patients had greater dispersion of delay and the values were dependent on the
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activation sequence. After 6 months of CRT, patients had increased contraction magnitudes in
native rhythm compared to baseline pre-CRT (baseline: -8.55%, 6 months: -10.14%, p=0.008).
CRT also prolonged native rhythm repolarization at the location of the LV pacing lead (baseline:
280 msec, 6 months: 306 msec, p=0.002).
Conclusions: ECGI-measured LV activation delay is an effective index for CRT patient
selection. CRT causes persistent improvements in contractile function, but increases dispersion
of repolarization, which could increase the risk of arrhythmias. Electromechanical delay
dispersion and sequence-dependence indicate that the timing of peak strains in STE is influenced
by mechanical factors such as opposing wall contractions in addition to the activation sequence.

3.2 Introduction
Heart failure (HF) is a progressive disease with high prevalence and high mortality that is a
major contributor to healthcare costs 1. HF is associated with adverse remodeling of the
ventricular myocardium that includes chamber dilatation, slow conduction, decreased myocyte
contraction amplitudes, and prolonged action potential durations 2-5. Approximately 30% of HF
patients have electrical dyssynchrony, apparent by a prolonged QRS duration on the ECG 6, an
indication of dyssynchronous ventricular contraction. Prolonged QRS duration and left
ventricular ejection fraction (LVEF) are inversely correlated, and HF patients with QRS
prolongation have higher all-cause mortality and may have a higher incidence of sudden death
than those with narrow QRS complexes 6.
Cardiac resynchronization therapy (CRT) improves the synchrony of ventricular contraction by
bi-ventricular pacing the ventricles. CRT has dramatically improved clinical outcomes for HF
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patients with prolonged QRS durations. Large clinical trials found that CRT improves patient
quality of life, reduces HF-related hospitalizations, prolongs patient survival, and may reduce the
risk of sudden cardiac death 7-10. CRT may also partially correct some of the pathological
abnormalities in HF, a process known as reverse remodeling. Animal studies found that CRT
restored cellular action potential duration (APD) and Ca2+ transients to normal levels 11,12.
Despite the widely reported benefits of CRT, the rate of patients who do not respond to the
therapy has been remarkably stable at around 30% 13.
Multiple attempts have been made to improve on patient selection criteria for CRT using various
electrical and mechanical indices of dyssynchrony. Multiple small studies reported promising
results applying 2D speckle tracking echocardiography (STE) to CRT patient selection. STE is
an imaging technique which tracks the characteristic speckled patterns in echocardiographic
images and computes deformation of the patterns to determine strain 14. Despite many promising
initial evaluations, the multicenter PROSPECT trial found that no echocardiographic measures of
dyssynchrony improved patient selection for CRT, and the EchoCRT trial, which evaluated CRT
in patients with mechanical dyssynchrony and a narrow QRS complex, was stopped for futility
with the conclusion that CRT was possibly detrimental in that patient cohort 15,16.
The disappointing performance of STE in CRT patient selection is an indication of gaps in our
understanding of the electromechanics of HF and CRT. A better understanding of the physiology
underlying response and non-response to CRT may advance future attempts to improve the
therapy. Basic science explorations of human cardiac electromechanics, such as whole-heart
computer simulations of electromechanical activity, may also contribute to better understanding
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of CRT. However, electromechanical data from non-diseased human hearts are currently lacking
17.

The present study combines STE with Electrocardiographic Imaging (ECGI; a noninvasive

method for cardiac electrophysiology mapping) 18 to study the electromechanics of CRT in HF
patients in situ. We imaged CRT patients longitudinally to determine baseline dyssynchrony,
acute resynchronization, and reverse remodeling after 3 and 6 months of CRT pacing. We also
collected ECGI and STE from a group of 20 healthy adult volunteers to serve as a control
baseline for comparison. In this group, we also performed tagged MRI 19 to provide a complete
three-dimensional data set of the normal electromechanical sequence of healthy adult hearts.

3.3 Methods
3.3.1 Patient Cohort
We enrolled 20 healthy adults and 30 HF patients undergoing CRT at Washington University in
St. Louis. Healthy volunteer demographics are provided in Supplemental Table S3.1, and HF
characteristics are provided in Supplemental Table 3.2. The study was approved by the Human
Research Protection Office at Washington University in St. Louis. All participants provided
written informed consent.

3.3.2 Electrocardiographic Imaging (ECGI)
The ECGI method, developed and validated in our laboratory, was described previously 20. A
schematic of the is presented in Supplemental Figure S3.1. Briefly, 256 uniformly distributed
ECGs were simultaneously recorded from the torso using a portable recording system
(ActiveTwo, BioSemi; The Netherlands). Patient-specific heart-torso geometries were obtained
from CRT patients using a thoracic CT scan gated at 70% of the R-R interval while wearing the
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recording electrodes. Heart-torso geometries of normal subjects (controls) were obtained using a
navigated anatomic MRI sequence. In these subjects, recording electrodes were replaced with
MRI-visible markers prior to the scan, for compatibility with MRI. The ECG recordings were
combined with the heart-torso geometries to reconstruct unipolar epicardial electrograms
noninvasively, using previously described methods 20. Typically, 1000 electrograms were
computed over the entire ventricular epicardium. Electrograms over the valve plane were
excluded from further analysis.

3.3.3 Echocardiography
Echocardiography was performed using a commercially available ultrasound imaging system
(Vivid 7, GE Healthcare, Milwaukee, WI). Longitudinal strain was assessed in standard 4chamber, 3-chamber (apical long axis), and 2-chamber apical views. Images were obtained using
the maximum framerate that allowed for viewing the entire left ventricle (LV) chamber, with a
typical frame rate of 70 frames per second. Strain curves in each apical view were computed
using vendor speckle-tracking software (EchoPAC, GE Healthcare, Milwaukee, WI). To
minimize the effect of noise on the timing of the strain curves, 3 beats were processed for each
view and averaged. LV volumes and ejection fractions were determined using Simpson’s biplane
method. Volumes and ejection fractions were also determined using the averaged values of 3
beats. In cases where the 2-chamber view could not be obtained (n = 5) the 4-chamber volume
parameters were used. We defined echocardiographic response as a decrease in LV end systolic
volume (LVESV) ≥ 15% and/or an increase in ejection fraction (EF) ≥ 5% at 6 month visit.
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3.3.4 Tagged MRI
Tagged MR images were obtained and analyzed using previously described methods 21. ECGgated images were obtained in short-axis and long axis views for a complete cardiac cycle
beginning at end-diastole. Short axis slices were obtained with 8mm spacing from the level of
the mitral valve to the LV apex. Four long-axis image sets were obtained in radially oriented
planes. Tissue tagging was performed on each image using a Spatial Modulation of
Magnetization radiofrequency tagging preparation, followed by 2-D balanced steady-state free
precession cine image acquisition. Tagged and non-tagged images were acquired during the
same breath hold to ensure similar anatomic positioning between images. Typical imaging
parameters were described previously 21.
The strain analysis has been described and validated

22.

Epicardial and endocardial wall

boundaries of the LV were defined in both short and long axis non-tagged images. Tag lines
were delineated using a semi-automated active contour algorithm. The attachment points of the
basal RV free wall were used in conjunction with a geometric model of the LV to create in finite
element model of the LV. Strain was measured based on the deformation of the tagged surfaces
throughout the cardiac cycle. 3D displacements were calculated from the movement of
intramural tag surface intersection points during systole. StressCheck software (ESRD, Inc. St
Louis, MO) was used to fit the displacement data and provide a continuous description of the
displacement throughout the LV. Strain values in circumferential and longitudinal directions
were calculated from this fitting.

62

3.3.5 Longitudinal CRT Studies
The first images of CRT patients were obtained after device implant but prior to the onset of
CRT pacing. This allowed us to determine the location of the pacing leads from the CT scan and
image the patients prior to any CRT-induced remodeling. Patients were imaged in their native
(un-paced) rhythm and at the onset of CRT pacing. Imaging was repeated in both paced and unpaced rhythms after 3 and 6 months of CRT pacing. To avoid the radiation exposure of
additional CT scans during follow-up visits, the recording electrodes were placed in the same
locations as on the initial visit using anatomical images from the initial scan to guide electrode
placement.

3.3.6 Analysis
Segmentation
Analysis of each imaging modality was performed blinded to the results of the other modalities.
The data were compared based on anatomical regions. The LV was segmented using a modified
version of the American Heart Association 17-Segment Model. The standard apical segments
were replaced with anterolateral, inferolateral, anteroseptal, and inferoseptal apical segments. For
the ECGI analysis, the lateral right ventricle (RV)was segmented using the same convention as
the lateral LV. Electrogram parameters for each region were computed using the mean value
from all electrograms within the region.
Electrogram Analysis
Activation times were computed from electrograms as the time of steepest negative timederivative of voltage (-dV/dtmax). Recovery times were computed as the steepest positive time63

derivative during the T wave (dV/dt max) 23. Activation-recovery intervals (ARIs, a surrogate for
local APD) were computed as the difference between recovery time and activation time. ECGIreconstructed ARI values have been validated against direct intraoperative epicardial mapping in
humans (see online supplement of Zhang et al 24). Electrogram fractionation was quantified
using the number of downward deflections between the QRS onset and T wave onset.
Electrograms with more than 2 deflections were considered “fractionated” deflections. ARIs and
fractionation were compared across visits in native rhythm only, to avoid the impact of altered
activation sequence on the indices. Parameters were computed at pacing sites by averaging
values of the 10 electrograms closest to the pacing lead locations.
Dyssynchrony Indices
We measured electrical dyssynchrony from the 12-lead ECG using the QRS duration. We
defined the QRS duration as the latest QRS end in any lead minus the earliest QRS onset in any
lead. We note that this definition differs from some measurements which report the QRS
duration as the maximum duration in any single lead. The total activation time was defined as the
latest epicardial activation time minus the earliest. We evaluated electrical dyssynchrony in
ECGI using two previously reported indices. The LV activation delay was defined as the mean
activation time in mid and basal lateral LV segments minus the mean activation time in mid and
basal lateral RV segments 25. The LV activation dispersion was defined as the standard deviation
of activation times within the LV 26.
We evaluated mechanical synchrony using analogous indices applied to the echocardiographic
strain data. The mechanical delay was defined as the mean time of peak strain in mid and basal
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lateral LV segments minus the mean time of peak strain in mid and basal septal segments. This
index was only computed for patients with at least two adequately-tracked segments in both the
lateral LV and the septum. The mechanical dispersion was defined as the standard deviation of
contraction times within the LV. This index was only computed in patients where strain data
could be obtained in all 3 apical views.
Temporal Alignment
ECGI and echocardiographic parameters were aligned temporally using the body surface ECG
from corresponding lead locations. Maxima or minima from the QRS voltage or voltage
derivatives were used to align the ECG traces. Tagged MRI data were aligned temporally with
the echocardiographic strain using the time of peak strain for each modality.
Statistical Analysis
Comparisons between controls and the HF population were performed using Wilcoxon rank-sum
tests. Changes due to acute and chronic CRT pacing were assessed using Wilcoxon signed-rank
tests. Correlations between parameters and volumetric reverse remodeling were performed using
Spearman correlation coefficients.

3.4 Results
3.4.1 Healthy Controls
The control population in this study was used to characterize normal sequences of activation and
contraction, and to establish normal ranges of electromechanical parameters (medians and
interquartile ranges of all control electrical and mechanical parameters are provided in
Supplemental Table S3.3). The epicardial activation sequence in healthy adults is very
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consistent in its overall pattern. In all patients, the anatomical segment of earliest activation was
located between the lateral RV and the anterior wall in mid or basal regions. The median time
between earliest and latest activation in controls was 42 msec, and the maximum value we
observed in the control group was 58 msec. In all controls the LV delay parameter was greater
than 0 (mean lateral LV activation was later than mean lateral RV activation) with a median
value of 14 msec. The activation isochrone map of a representative control is presented in Figure
3.1.

Figure 3.1. Activation isochrones in a healthy adult. Earliest activation in healthy adults falls between the lateral
right ventricle (RV) and anterior wall. Atria and left anterior descending coronary artery are shown in gray. Right
ventricular outflow tract shown in blue. Left ventricular outflow tract shown in pink. LV: left ventricle; RA: right
atrium; LA: left atrium.
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The sequence of LV strain in controls was similarly consistent. LV segments contractions were
highly synchronous and reached peak strain approximately 430 msec after the onset of the QRS
complex (medians and interquartile ranges for all control parameters are provided in
Supplemental Table S3.3). The median mechanical delay was 12 msec, though there was more
variability than in the electrical delay parameter and several subjects had negative values (peak
septal strain after peak lateral LV strain). The mean delay between electrical activation and peak
strain within anatomical segments was 375 msec. Figure 3.2 presents the contraction sequence
and mechanical parameters for a representative control. Combining tagged MRI with ECGI
yields high resolution 3D maps of epicardial voltage and LV displacement and strain. An
example of the 3D electromechanical sequence is presented in Figure 3.2b, and the
Supplemental Movie.
Control repolarization was consistent with previous descriptions. The mean epicardial ARI value
in the controls had a median value of 238 msec, which shows good agreement with the
previously reported value of 235 msec 27. The larger size of the control group in this study
compared to the prior study allowed us to measure the difference in mean epicardial ARI
between healthy male and female adults. Males had a median of 229 msec with 19 msec
interquartile range, and females had a median of 261 msec with 23 msec interquartile range (p =
0.001). Representative ARI maps for a control male and a control female are presented in Figure
3.3.
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A

B

Electrical Activation

Contraction

Relaxation

Figure 3.2. Healthy adult excitation and contraction. A. Speckle tracking echocardiography (STE) strain curves (top
plot) plotted below the ECG. Electrical activation times are indicated in the plot with vertical lines (dashed lines
indicate right ventricular activation as an approximation of septal activation time). Dotted line indicates aortic valve
closure. The timing of peak strain within anatomical segments (top bullseye plot) was homogeneous within the LV.
Regional electromechanical delay values (bottom bullseye plot) were computed by subtracting the electrical
activation time from the time of peak strain within regions. B. Tagged MRI was performed on the controls, allowing
for detailed electrical and mechanical imaging in the same coordinate system. Electrical activation is indicated as a
transition from dark to light ventricular surface (left image). Tagged MRI displacement markers (colored dots;
colors represent angular position within the LV) show the 3D contraction of the LV. An animation of the sequence
is included in the Supplemental Movie.
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Figure 3.3 Activation-recovery interval (ARI) maps for a healthy adult male and female. Mean epicardial ARI
values in female controls were approximately 30 msec longer than male controls. The longest ARI values were
generally observed in the basal region.

3.4.2 Heart Failure and Cardiac Resynchronization Therapy
Electrical Activation
The native (un-paced) epicardial activation sequence in HF patients was prolonged compared to
controls (statistical comparison to controls provided in Supplemental Table S3.3, changes due
to acute CRT pacing onset provided in Supplemental Table S3.4). The most common pattern of
epicardial activation in HF patients was characterized by a normal RV activation with varying
degrees of delay in the lateral LV. In the majority of CRT patients, the primary factors in the
efficacy of acute resynchronization were the baseline level of LV delay and the location of the
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LV lead. Figure 3.4 presents representative echocardiographic responders and nonresponders.
The responders (patients 25 and 27) have high levels of baseline dyssynchrony with LV leads
located in the region of late activation. The acute onset of CRT pacing resulted in significant
improvement in the LV delay parameter. In contrast, the first nonresponder (patient 12) had a
lower degree of baseline LV dyssynchrony, and the onset of pacing resulted in a smaller
improvement in synchrony compared to the responders. The second nonresponder (patient 13)
had a high degree of baseline dyssynchrony, however, the anterior location of this patient’s lead
reduced the effectiveness of pacing at synchronizing the ventricles.

Figure 3.4 Activation isochrone maps in CRT patients in native rhythm prior to CRT pacing and at the onset of
pacing. Pacing lead locations in the CRT-paced images are indicated with black spheres. LV activation delay values
in each rhythm and the decrease in the absolute value of the index (“Improvement”) are indicated to the right of the
images. Echocardiographic responders (top 2 rows) generally had high levels of dyssynchrony at baseline, which
was substantially improved by CRT pacing. Echocardiographic nonresponders often had less baseline dyssynchrony
(row 3) or ineffective lead placement (row 4).
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While baseline dyssynchrony and LV lead placement were major factors in acute
resynchronization, the presence of scar affected the native rhythm and the efficacy of CRT
pacing in several patients. Electrograms from regions of scar are characteristically low-amplitude
and fractionated. By computing the number of steep downward deflections in electrograms we
were able to quantify and visualize the electrophysiological substrate of scar. We found that HF
patients had a higher percentage of fractionated electrograms than controls (median 1.77% in HF
vs 0.38% in controls, p = 0.001). There were 5 patients with very high levels of epicardial
fractionation (6 standard deviations above the control mean). Out of these 5 patients, 3 were
nonischemic, 1 was ischemic, and 1 had mild nonosbstructive coronary artery disease. Three of
these patients are presented in Figure 3.5.
Patient 10 (Figure 3.5, top row) demonstrates the impact that scar can have on the native
activation sequence. The patient has a large lateral region of fractionation (left column), and the
patient’s native activation has a very long activation delay in the region of scar (middle column).
The region of late activation is very small in this patient, and the onset of CRT pacing (right
column) provides little to no improvement in synchrony. Patients 8 and 30 (Figure 3.5, middle
and bottom rows, respectively) demonstrate the importance of lead placement in relation to scar.
Patient 8 has an LV lead located in an inferolateral scar region, which resulted in delayed
activation of the more anterior regions of the LV. Patient 30 had a region of scar in the basal
lateral LV, but the patient’s LV lead was located in the center of a region of healthy
myocardium. This patient’s synchrony improved substantially and the patient was an
echocardiographic responder.
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Figure 3.5 Maps of the number of deflections in each electrogram (first column), native rhythm activation (middle
column), and CRT-paced activation (right column). Electrograms from the scar region and remote un-fractionated
regions are provided to the left of the maps. Numbers indicate electrogram locations. Pacing electrode locations are
indicated in the fractionation and CRT-paced activation maps with black or white spheres. Patients with high
degrees of fractionation sometimes had atypical native rhythm activation sequences (top row). Pacing within regions
of fractionation was less effective at activating nearby regions outside the scar (middle row). Patients with large
regions of fractionation could still be resynchronized effectively when paced outside of the fractionated region
(bottom row).

Contraction
Contraction in CRT patients was dyssynchronous and impaired. CRT patients had larger presystolic stretch and low peak contraction amplitudes than controls (full statistical comparisons
presented in Supplemental Table S3.3). Figure 3.6 (top) illustrates the native rhythm
contraction sequence for a CRT patient. Electrical activation of the lateral LV is delayed relative
to the other segments (vertical lines). The lateral LV was stretched by the septal wall contraction
prior to its own contraction and the lateral wall segments reached peak contraction after aortic
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Figure 3.6. Native rhythm strains in heart failure (HF) patients (top) were dyssynchronous and lower in amplitude
than controls. Lateral regions often stretched prior to contraction and reached peak strain after aortic valve closure
(dotted line). Many regions were later to reach peak strain (top bullseye) than controls. The mean electromechanical
delay in HF patients was the same as in controls, but the values within the LV showed greater dispersion (bottom
bullseye). The Acute onset of CRT (bottom) decreased pre-systolic lateral wall stretch. Peak strain timing values did
not capture synchrony improvements effectively. Regional electromechanical delay values were not consistent
across different activation sequences.
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valve closure (vertical dotted line). While the overall pattern of delayed LV contraction is
apparent from the strain curves, it is difficult to extract meaningful markers of contraction timing
from the plots because of the influence of opposing contraction and low amplitudes in some
regions. In this patient, several of the septal wall segments reach peak strain after the lateral wall,
despite the apparent overall pattern of delayed LV contraction. The mean electromechanical
delays observed in HF patients closely matched control values, however, the dispersion of
electromechanical delays within the LV were much larger.
The onset of CRT pacing improved the overall synchrony of the strain sequence (Figure 3.6,
bottom). Lateral wall stretch is reduced, but peak strain values remained low compared to
controls. The dispersion of electromechanical delay values in the LV was not corrected by the
onset of CRT, and values within regions varied between the CRT and native rhythm. This
indicates that the electromechanical delay cannot be regarded as an activation sequenceindependent property of the underlying tissue.
Volumetric Reverse Remodeling
Of the 30 CRT patients, 22 patients completed the study and could be classified as
echocardiographic responders or nonresponders. Out of these, 7 (32%) were nonresponders,
consistent with the rate of nonresponders observed in most CRT studies. We used Spearman’s
rank correlation coefficient to correlate baseline native rhythm electrical and mechanical
parameters with change in LVESV (Supplemental Table S3.5). In general, we found that
electrical dyssynchrony parameters were much more predictive of reverse remodeling than
mechanical dyssynchrony and function parameters. Each ECGI index of electrical dyssynchrony
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(total activation time, LV electrical delay, and LV electrical dispersion) correlated with LVESV
remodeling more strongly than QRS duration and all of the mechanical indices. The most
predictive parameter was the LV electrical delay (rho = -0.722, p < 0.001). In addition to
baseline parameters, we correlated improvements in synchrony parameters at the onset of CRT
pacing with change in LVESV (Supplemental Table S3.6). In this evaluation, acute
improvements to the LV activation delay and mechanical dispersion had the highest correlations
with LVESV remodeling (rho = 0.679 and rho = 0.671, respectively). However, these
correlations were both lower than the correlation between baseline LV delay and LVESV
remodeling.
Electrical and Mechanical Remodeling
To assess changes in electrical and mechanical properties induced by chronic CRT pacing, we
compared electrical and mechanical parameters in native rhythm prior to the onset of CRT
pacing to native rhythm after 6 months of CRT. We found no significant changes in electrical or
mechanical synchrony parameters when comparing native rhythm before and after chronic CRT
pacing (Supplemental Table S3.7), indicating that the underlying level of dyssynchrony
remains unchanged. Despite the unchanged native rhythm activation sequence, we found a
persistent improvement in native rhythm contraction magnitudes after 6 months of CRT
(Baseline median: -8.55%, Remodeled median: -10.14%, p = 0.008) and sustained EF
improvement (Baseline median: 24%, Remodeled median: 27%, p < 0.001). Figure 3.7
demonstrates the improved contraction in 4 CRT patients.
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Figure 3.7 Peak contraction magnitudes are improved during the course of CRT. Values at each visit were
determined from un-paced native rhythm beats, indicating persistent improvements in contraction as a result of
chronic CRT pacing.

Prior to the onset of CRT, HF patients’ mean epicardial ARIs were prolonged by about 45 msec
compared to controls (Supplemental Table S3.3). After 6 months of CRT, mean epicardial
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ARIs were largely unchanged (Supplemental Table S3.7). However, native rhythm ARIs near
the LV pacing site were prolonged by a median value of 23 msec (p = 0.002). Figure 3.8
presents baseline and remodeled ARI maps for 2 patients.
We correlated the changes in contraction and ARI prolongation at the LV pacing site with the
change in ESV. The change in contraction was correlated with ESV change, but the LV ARI
change was not (Supplemental Table S3.8). This suggests that the contraction improvement is
part of the beneficial reverse remodeling changes induced by CRT, while the ARI prolongation
is an effect of LV pacing that is not related to the beneficial reverse remodeling process.

Figure 3.8. Epicardial activation-recovery interval (ARI) maps in heart failure (left) and after 6 months of CRT
pacing (right). Heart failure patients had longer mean ARI values than control subjects at baseline. After 6 months of
CRT pacing, ARI values were prolonged at the location of the left ventricle (LV) pacing lead.
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3.5 Discussion
This paper presents the first combined application of ECGI and strain imaging in patients,
thereby providing electrical and mechanical data from the same human hearts in situ. The
following observations were made: 1. The LV electrical activation delay, determined from
ECGI, outperforms mechanical measures of synchrony and is the best index for identifying
potential responders to CRT. It also performs better than the QRS duration on the 12 – lead ECG
that constitutes the standard of care in clinical practice. 2. Taking advantage of the panoramic
mapping that ECGI provides, we discovered that LV pacing in CRT prolongs the APD in the
region surrounding the electrode. The localization of the APD prolongation indicates that CRT
pacing increases heterogeneity of repolarization, a known mechanism of arrhythmia. 3. We
defined a novel parameter, the electromechanical delay between activation and peak strain within
anatomical segments. We measured greater heterogeneity of the electromechanical delay in
patients with dyssynchronous HF than controls. We also found that the electromechanical delay
within regions is dependent upon the activation sequence. This implies that the timing of peak
strains on echo does not merely reflect the electrical activation sequence, but is affected by the
mechanics of opposing wall contractions. This may explain, in part, why STE has not seen
greater success as a tool for CRT patient selection. 4. Through noninvasive assessment of healthy
adult hearts, we demonstrated that the ARI on the epicardial surface in females is longer than
males. Further study of gender-specific differences in repolarization with ECGI may help explain
why women are more susceptible to arrhythmias associated with the long QT syndrome. 5. Using
tagged MRI, we provide a high-resolution 3D description of contraction of healthy hearts that is
co-registered spatially and temporally with detailed electrical activation and repolarization maps.
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These data could be beneficial for constraining mathematical models and validating computer
simulations of human cardiac electromechanics.

3.5.1 Control Physiology
The control population in this study is the largest group of healthy adults imaged with ECGI to
date. This group served as a control for the current study and is valuable in that capacity as ECGI
is applied to new pathologies. Additionally, the larger size of this study compared to a previous
ECGI study of healthy adults allowed us to quantify the difference in epicardial repolarization
between males and females. The longer repolarization we find in females is consistent with ECG
findings that women have longer QTc intervals than men 28. Exploring the link between this
repolarization prolongation and the higher susceptibility of women to torsade de pointes would
be an interesting application of ECGI 29.
The combination of ECGI, STE, and tagged MRI provide very detailed 3D characterizations of
the healthy adult heart in situ. Tagged MRI provides detailed 3D displacement and strain data in
the LV, however, the exact timing of the image acquisition relative to the ECG is opaque. By
collecting STE, which is acquired with the body-surface ECG, in the same patients, we were able
to align the strain curves temporally using the time of peak strain in each modality. The result is
a detailed combination of electrical and mechanical sequences in healthy adult hearts. This data
set may be particularly useful to constrain and validate mathematical models of the cardiac
electromechanics.

79

3.5.2 Response to CRT
The initial evaluations of ECGI in CRT patients were retrospective studies of ischemic and
nonischemic patients 25,26. These studies evaluated two dyssynchrony indices: the LV activation
delay and the LV activation dispersion. In the present prospective evaluation of electrical
dyssynchrony and response to CRT, we found that both indices out-performed the body-surface
ECG and mechanical indices, and that the LV delay index was the best predictor of volumetric
reverse remodeling (Supplemental Table S3.5). That is, high level of inter-ventricular
dyssynchrony, as measured by ECGI, is a good predictor of response to CRT. This is in
agreement with a prior prospective ECGI study of CRT patients that found the LV delay
(referred to in that study as ventricular electrical uncoupling) was superior to QRS duration at
identifying responders 30. A recent torso-tank study has directly validated ECGI reconstructions
of this index compared to direct epicardial measurements 31. In this study, we found that baseline
electrical dyssynchrony was more correlated with LVESV remodeling than the improvement of
synchrony at pacing onset. However, it would be valuable to explore whether using ECGI
interactively to optimize lead placement and pacing timing would offer patients additional
benefits.
An evaluation of ECGI in patients with pediatric congenital heart disease found that placing the
LV lead in the site of latest activation resulted in favorable outcomes 32. The present study
demonstrated the ability of ECGI to image electrophysiological scar and showed its influence on
dyssynchrony and pacing efficacy. Prior studies, using other imaging modalities, have
demonstrated the importance of scar and its location relative to pacing leads for predicting CRT
response 33. However, ECGI offers the unique possibility of quantifying baseline dyssynchrony
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with indices that may outperform the current standard of practice, identifying regions of delayed
activation, imaging myocardial scar substrate, and evaluating the efficacy of lead location and
other pacing parameters with a single imaging modality in real-time.

3.5.3 Remodeling
We found that contraction magnitudes increased as part of the CRT reverse remodeling process,
and that the increased magnitudes persisted when comparing patients’ baseline native rhythm to
their native rhythm after 6 months of CRT. This, coupled with the absence of any activation
sequence changes, indicates that the increased contraction was due to mechanical improvements.
Cellular studies report decreased contraction amplitudes in myocytes isolated from failing human
hearts 2. Animal studies have reported that CRT restores intracellular Ca2+ transients to normal
levels, which could improve contraction 11. However, Ca2+ transient changes were associated with
a reversal of APD prolongation 11,12, which we did not observe. Another possible mechanism for
increase in contraction amplitudes is that they are secondary to the volumetric reverse remodeling.
In simplified models, ventricular wall stress is proportional to chamber diameter as governed by
the Law of Laplace 34. The strong correlation between LVESV decrease and contraction amplitude
supports this as a possible mechanism.
Multiple animal studies demonstrated ARI shortening as a result of CRT induced reverse
remodeling

11,12.

In our study, we find not only that mean epicardial and mean LV ARIs do not

decrease, but that at the site of the LV pacing lead native-rhythm ARIs increase by a median value
of 23 msec. The discrepancy between our observations and the animal studies could be due to the
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species differences, or the nature of the heart failure model, which was induced by RV tachypacing
over a period of weeks to months.
The ARI prolongation we observed was not strongly correlated with LVESV, suggesting that it
may be an effect of the pacing, rather than the reverse remodeling process. Prior work showed that
pre-excitation due to RV pacing and Wolff-Parkinson-White syndrome were both associated with
prolonged ARI in the region of pre-excitation

35,36.

In the present study, we observed ARI

prolongation at the LV pacing site, but not the RV pacing site. It is noteworthy that CRT devices
are often programmed so that the RV is activated by the intrinsic conduction system (illustrated in
Figure 3.4, patients 25 and 27). This may cause less consistent pre-excitation at the RV lead
location than the LV location and consequently a minimal effect on ARI.
There have been conflicting reports about whether CRT reduces or increases the risk of arrhythmia
10,37.

The finding of increased dispersion of repolarization due to ARI prolongation in the region

of pacing suggests a mechanism for CRT increasing the risk of arrhythmia. The actual influence
of this mechanism in the context of beneficial remodeling is unclear, however, this mechanism
may be more significant in nonresponders. Because the ARI prolongation appears to be caused by
the LV pacing and not reverse remodeling, nonresponders may be subjected to increased
heterogeneity in repolarization without the benefits of improved LV function, which may be
detrimental to their overall health. This underscores the importance of clinical criteria that properly
exclude patients who will not benefit from CRT from receiving the treatment. Given these
observations, it would be interesting to explore whether emerging LV pacing techniques such as
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LV endocardial pacing, which may carry additional benefits

38,

have a more favorable effect on

repolarization.

3.5.4 Conclusion
The data support the utility of ECGI for improving patient selection for CRT. The timing of peak
strain in STE is not a reliable index of local activation time when dyssynchrony is present. CRTinduced reverse remodeling improves contraction but prolongs repolarization at the LV pacing
site, augmenting dispersion of repolarization. Additional studies are necessary to determine
whether electrogram fractionation maps or interactive ECGI device optimization offer additional
benefits to CRT treatment of HF patients.
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Chapter 3 Appendix
Supplemental Table S3.1: Control Population
ID
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20

Age
27.8
28.1
28.3
27.5
27.6
27.0
31.9
27.3
29.4
25.1
24.9
49.0
22.1
35.5
24.1
34.8
24.4
22.0
53.7
31.0

Sex
M
M
M
F
M
M
M
M
F
F
M
F
F
M
M
F
F
F
F
F

Race
Asian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
African American
Caucasian
Caucasian
Caucasian
African American
Asian
Caucasian
Caucasian
Caucasian
Caucasian

Ethnicity
Not Hispanic
Not Hispanic
Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic

Healthy adult volunteer demographics.
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Supplemental Table S3.2: CRT Population
ID
EM1
EM2
EM3
EM4
EM5
EM6
EM7
EM8
EM9
EM10
EM11
EM12
EM13
EM14
EM15
EM16
EM17
EM18
EM19
EM20
EM21
EM22
EM23
EM24
EM25
EM26
EM27
EM28
EM29
EM30

Age
53.0
64.0
71.9
63.3
54.4
73.0
66.3
59.8
69.5
62.4
69.3
67.5
60.1
54.5
77.6
64.0
52.5
78.7
74.7
34.7
77.5
81.1
55.3
74.1
51.3
72.4
40.5
62.4
61.4
64.1

Sex
F
F
M
M
M
F
M
M
F
M
F
M
M
F
M
F
M
F
F
M
M
M
M
M
F
M
F
M
M
M

Race
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
African American
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
African American
Caucasian
African American
African American

Ethnicity
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic
Not Hispanic

Etiology
NICM
NICM
NICM
NICM
NICM
NICM
ICM
NICM
NICM
ICM
NICM
ICM
ICM
NICM
ICM
NICM
NICM
ICM
NICM*
NICM
ICM
ICM
ICM
NICM
NICM
ICM
NICM
NICM
NICM
NICM

Cardiac resynchronization therapy patient demographics. ICM: Ischemic Cardiomyopathy. NICM: Nonischemic
cardiomyopathy
*Mild nonobstructive coronary artery disease
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Supplemental Figure S3.1: ECGI Methodology

Schematic of the ECGI procedure. Body-surface potentials are recorded from the torso surface using a portable
recording system (top). The heart-torso geometry is obtained using a computed tomography (CT) or magnetic
resonance imaging (MRI) scan (bottom). The heart-torso geometry and torso potentials are combined and the
inverse problem is solved to reconstruct unipolar epicardial electrograms. Electrograms are processed to determine
local electrical parameters of interest (right frame).
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Supplemental Table S3.3: Heart Failure Comparison to Controls
Parameter
ECG
QRS duration (msec)
Ejection fraction (%)
End systolic volume (mL)
Volume
End diastolic volume (mL)
Stroke volume (mL)
Total activation time (msec)
LV activation delay (msec)
LV activation dispersion (msec)
Mean epicardial ARI (msec)
ECGI
Mean LV ARI (msec)
Mean RV ARI (msec)
Percentage of fractionated electrograms (%)
Fractionated deflections per electrogram
Total strain time (msec)
Mechanical delay (msec)
Mechanical dispersion (msec)
Strain
Mean peak strain time (msec)
Mean peak contraction (%)
Max pre-systolic stretch (%)
Mean electromechanical delay (msec)
Electromechanical Delay
Electromechanical delay dispersion (msec)

Control
Median
87
57
46
111
63
42
14
9
238
240
240
0.38
0.0038
98
12
28
427
-20.64
2.57
375
25

Control
IQR
16
3
20
36
18
12
7
3
32
23
50
1.03
0.0103
42
53
10
40
2.82
1.86
40
15

Heart Failure
Median
154
24
122
160
39
123
81
24
284
292
281
1.77
0.0179
196
91
70
432
-8.78
4.38
373
57

Heart Failure
IQR
31
4
56
72
19
33
48
9
26
25
31
2.11
0.0254
67
112
19
82
2.42
3.48
50
19

p
p < 0.001
p < 0.001
p < 0.001
0.002
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
0.532
p < 0.001
0.003
0.940
p < 0.001

Control and heart failure baseline electrical and mechanical parameter comparison. All parameters were measured in
native rhythm. Groups were compared using Wilcoxon rank-sum tests.
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Supplemental Table S3.4: Acute Resynchronization
Native
Median
154
24
122
160
39
123
81
24
196
91
70
-8.78
4.38
373
57

Parameter
ECG
QRS duration (msec)
Ejection fraction (%)
End systolic volume (mL)
Volume
End diastolic volume (mL)
Stroke volume (mL)
Total activation time (msec)
ECGI
LV activation delay (msec)
LV activation dispersion (msec)
Total strain time (msec)
Mechanical delay (msec)
Strain
Mechanical dispersion (msec)
Mean peak contraction (%)
Max pre-systolic stretch (%)
Mean electromechanical delay (msec)
Electromechanical Delay
Electromechanical delay dispersion (msec)

Paced
Median
128
27
114
168
43
104
10
29
182
-15
63
-8.78
3.6
391
61

Paired Delta
Median
-37
3
1
5
7
-19
-62
11
-14
-96
-9
0.22
-1.23
10
8

Paired Delta
IQR
31
4
20
29
9
29
53
2
75
91
40
1.97
2.19
50
33

p
p < 0.001
p < 0.001
0.914
0.094
p < 0.001
0.004
p < 0.001
0.057
0.223
p < 0.001
0.046
0.549
0.009
0.097
0.039

The effect of acute CRT pacing onset on electrical and mechanical parameters in heart failure patients. Changes
were evaluated using Wilcoxon signed-rank tests.
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Supplemental Table S3.5:
LVESV Remodeling Correlation with Baseline Parameters
Parameter
QRS duration (msec)
Total activation time (msec)
LV activation delay (msec)
LV activation dispersion (msec)
Mean epicardial ARI (msec)
ECGI
Mean LV ARI (msec)
Mean RV ARI (msec)
Fractionated deflections per electrogram
Fractionated deflections per electrogram at LV pacing site
Total peak strain time (msec)
Mechanical delay (msec)
Strain
Mechanical dispersion (msec)
Mean peak contraction (%)
Mean pre-systolic stretch (%)
Activation-peak strain delay (msec)
Electromechanical Delay
Activation-peak strain delay spread (msec)
ECG

Spearman's Rho
-0.486
-0.583
-0.722
-0.588
-0.110
0.168
-0.373
0.241
0.387
-0.425
0.132
-0.585
0.009
-0.324
-0.225
-0.204

p
0.023
0.005
p < 0.001
0.005
0.625
0.454
0.088
0.280
0.075
0.101
0.639
0.019
0.978
0.221
0.419
0.466

Correlations between the change in left ventricular end-systolic volume (LVESV) after 6 months of CRT pacing and
baseline electrical and mechanical parameters in heart failure patients. All parameters were measured in native
rhythm. Correlations were determined using Spearman’s Rho tests.
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Supplemental Table S3.6:
LVESV Remodeling Correlation with Acute Dyssynchrony Index Changes

ECG
Volume
ECGI

Strain

Parameter
QRS duration (msec)
Ejection fraction (%)
Total activation time (msec)
LV activation delay absolute value (msec)
LV activation dispersion (msec)
Total peak strain time (msec)
Mechanical delay absolute value (msec)
Mechanical dispersion (msec)

Spearman's
Rho
0.505
0.025
0.407
0.679
0.545
0.583
0.013
0.671

p
0.017
0.934
0.061
p < 0.001
0.010
0.023
0.965
0.008

Correlations between the change in left ventricular end-systolic volume (LVESV) after 6 months of cardiac
resynchronization therapy (CRT) pacing and the change in dyssynchrony parameters due to the acute onset of CRT
pacing. Correlations were determined using Spearman’s Rho tests.
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Supplemental Table S3.7:
Native Rhythm Changes after 6 Months of CRT
Parameter
ECG
QRS duration (msec)
Ejection fraction (%)
End systolic volume (mL)
Volume
End diastolic volume (mL)
Stroke volume (mL)
Total activation time (msec)
LV activation delay (msec)
LV activation dispersion (msec)
Mean epicardial ARI (msec)
Mean LV ARI (msec)
ECGI
Mean RV ARI (msec)
LV pacing site ARI (msec)
RV pacing site ARI (msec)
Percentage of fractionated electrograms (%)
Fractionated deflections per electrogram
Total peak strain time (msec)
Mechanical delay (msec)
Strain
Mechanical dispersion (msec)
Mean peak contraction (%)
Mean pre-systolic stretch (%)
Activation-peak strain delay (msec)
Electromechanical Delay
Activation-peak strain delay spread (msec)

Baseline
Median
154
24
125
167
40
123
82
24
282
288
280
280
293
1.54
0.0171
196
88
70
-8.55
4.59
367
57

6 Months
Median
157
27
121
171
48
115
81
25
288
293
283
306
297
1.85
0.0235
210
81
66
-10.14
3.48
381
50

Paired Delta
Median
5
6
-22
-11
8
-4
2
1
6
6
4
23
3
0.56
0.0046
14
-6
0
-1.31
-1.13
14
-7

Delta IQR
11
7
47
49
19
14
20
4
28
26
28
36
30
2.16
0.0492
77
65
26
2.93
4.22
45
20

p
0.164
p < 0.001
0.046
0.306
0.005
0.178
0.858
0.211
0.408
0.211
0.833
0.002
0.291
0.511
0.565
0.891
1.000
0.228
0.008
0.438
0.169
0.135

The effects of 6 months of cardiac resynchronization therapy pacing on heart failure patients’ electrical and
mechanical parameters. All parameters at each visit were computed from native rhythm beats. Changes were
evaluated using Wilcoxon signed-rank tests.
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Supplemental Table S3.8:
Correlation of LVESV Remodeling with ARI and Contraction Remodeling

Parameter
LV pacing site ARI (msec)
Mean peak contraction (%)

Spearman's Rho
-0.206
0.618

p
0.356
0.013

Correlation between the change in left ventricular end-systolic volume after 6 months of cardiac resynchronization
therapy (CRT) pacing and the changes in ARI and contraction remodeling. Correlations were determined using
Spearman’s Rho tests.
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Chapter 4: Concluding Remarks and Future
Work
4.1 Concluding Remarks
This thesis demonstrated the utility of ECGI as a research and clinical tool by combining ECGI
with complimentary imaging techniques to study new patient populations. The results of this
work revealed new aspects of human heart physiology and point to roles for ECGI in the clinical
care of patients.
The combination of ECGI and LGE imaging in ARVC patients revealed electrical abnormalities
which co-localized with regions of visible scar. ARVC patients had abnormalities in conduction
and repolarization. PVCs were common in ARVC patients, and they typically originated in
regions of scar and electrical abnormalities. This finding implicates the electrical and structural
abnormalities as mechanistic contributors to the formation of arrhythmia triggers in ARVC
patients. In a young ARVC patient, we found that conduction abnormalities were visible before
structural abnormalities. This suggests that the sensitivity of ECGI for detecting conduction
abnormalities can play an important role in the early concealed phase of the disease.
By combining ECGI and strain imaging in CRT patients, we demonstrated that ECGI is effective
for predicting response to CRT. The most sensitive index for predicting response to CRT was the
LV activation delay determined by ECGI. STE indices were less effective predictors of response.
The time delay between electrical activation and peak contraction within anatomical regions was
variable and rhythm-dependent in CRT patients. This indicates that mechanical factors other than
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the activation sequence influence the time of peak strain by STE. We showed that CRT pacing
causes improvements in contraction that persist even when the pacing is temporarily disabled.
We also found that CRT prolongs repolarization at the LV pacing site, which could increase the
risk of arrhythmia.

4.2 Future Work
There are numerous opportunities for continuing to build upon this thesis and the work that
preceded it. In the context of ARVC, this thesis demonstrated that ECGI detects electrical
abnormalities in ARVC and linked them to PVCs, which can trigger dangerous arrhythmias. In
order to relate the ECGI findings to the underlying scar substrate, the study used MRI-based
LGE. A downside of using MRI to study patients with ARVC is that patients with ICDs were
excluded from the study group because ICDs carry a contraindication for MRI. Because patients
with a history of arrhythmia typically receive ICDs, the study population did not include any
patients with a history of arrhythmia. Therefore, the study could not evaluate how predictive the
various abnormalities were of arrhythmia. An important future study would be to compare
patients with a history of arrhythmia to those without, and then determine whether any ECGI
indices predict the risk of arrhythmia. Currently, the only widely accepted criterion for ICD
implantation is a history of ventricular tachycardia. Because the first occurrence of ventricular
tachycardia can be deadly, improved predictors of arrhythmia risk in ARVC patients are urgently
needed.
A logical continuation of CRT research in this thesis would be to perform a larger prospective
study to compare outcomes in patients selected for CRT by ECGI criteria to outcomes in patients
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selected with conventional criteria. There are obvious benefits to delivering effective treatment
to more patients. There are also benefits to accurately identifying patients who will not respond
to the treatment. As the EchoCRT clinical trial showed, CRT may be detrimental in patients who
do not need the treatment. Our data suggest that heterogenous repolarization may contribute to
the detrimental effects of pacing these patients. Accurate identification of nonresponders could
help decrease healthcare costs and direct more effective treatment strategies to nonresponders.
Another avenue for exploration is using ECGI to optimize CRT pacing settings. The relative
timing of pacing leads is an important factor in the overall effectiveness of pacing. Even modest
improvements over current practices could have a very large impact because of the large
population of heart failure patients.
There are many important applications outside of ARVC and CRT that should be further
explored. One of the most interesting recent developments in the field of cardiac
electrophysiology is the emergence of noninvasive ablation. Treatment for arrhythmia is
traditionally performed in an invasive procedure in which a catheter is guided to the heart and
used to burn regions of tissue that are responsible for starting or sustaining arrhythmia. A recent
pilot study performed at Washington University in St. Louis tested the use of radiation therapy as
an alternative to the standard invasive ablation procedure 1. Noninvasive ablations were
performed on 5 patients with ventricular tachycardia that was refractory to conventional
treatment. Prior to ablation, the patients were mapped with ECGI, and ECGI maps were used to
help guide the ablation target. The treatment resulted in a 99.9% reduction in ventricular
tachycardia in the patient cohort. The combination of noninvasive electrical mapping and
noninvasive ablation are a natural pairing, and evaluation of this approach is already underway in
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a larger cohort. While the early results of this work are very exciting, there are many
improvements that can be made. Improvements to the delivery of radiation should include
incorporation of cardiac motion. Currently, the target is chosen for optimal delivery throughout
the cardiac cycle, but unnecessary radiation delivery to healthy surrounding tissue could be
reduced by incorporating cardiac motion. This thesis demonstrated that ECGI is compatible with
tagged MRI, which tracks the motion of the left ventricle throughout the cardiac cycle. Beyond
tagged MRI, the compatibility of ECGI with CT and MRI enables its combination with
numerous other imaging techniques that could improve radiation delivery.
Finally, the ultimate success of any clinical tool depends on evidence-based guidelines for its
application and its cost-effectiveness for improving patient outcomes. While ECGI was applied
purely as a research tool in this work, the technique is now commercially available. In order to
maximize the long-term benefits that ECGI can offer, future research must continue to prove the
benefits of clinical ECGI, and commercial development must ensure that those benefits are costcompetitive within the context of current standards of practice.
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